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ABSTRACT 
 
Clinical immunohistochemistry (IHC) techniques are not yet fully standardized. In 
this project, a standardization method was developed and tested for proficiency testing 
(PT) in external quality assurance (EQA) and quality control (QC) in clinical IHC 
laboratories. The breast cancer markers estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor 2 (HER2) were used as a model system. 
Digital image analysis (IA) was used in conjunction with new calibrated and 
standardized cell line microarrays (CLMA). CLMAs built from nine formalin-fixed 
paraffin-embedded (FFPE) breast cancer cell lines were used for both QC controls and 
PT samples, instead of traditionally used FFPE tissues, in the standardization of breast 
cancer IHC. IA was used for measurement of IHC results, and compared to evaluation 
by the traditional expert-assessment method. 
Laboratory Score: Reference Score Ratio (LSRSR) was derived from Histo-Scores 
(HScores) determined by IA. HScores and LSRSRs were examined statistically and 
evaluated as histograms and boxplots to summarize and rank participant laboratory 
EQA results, in comparison to a reference sample or reference laboratories in two 
consecutive Canada-wide EQA runs. 
LSRSR-derived reference ranges were highly sensitive in evaluating laboratory 
EQA performance in PT as well as for monitoring of controls for QC. Laboratory on-slide 
tissue and cell-line IHC QA controls were assessed using IA and Levey Jennings QC 
charts. These charts were determined to be an excellent way to observe trending in 
laboratory IHC staining over time, particularly when cell line controls were used. This 
approach also reduced the time and labor costs for PT evaluation.  
Overall, cell line calibration controls were functionally equivalent or better than 
tissue-based controls in QC and PT mainly because of cell line biological homogeneity 
and sample availability. This study identified an optimal design for preparation of IHC 
cell line controls and PT samples for breast cancer markers. Optimal, intermediate 
staining cell line IHC controls were identified for all three breast cancer markers. 
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Using IA with LSRSR and cell line samples is recommended for standardization of 
IHC methodology. This approach advances QA for diagnostic IHC and when 
implemented will improve patient care. 
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1.0 LITERATURE REVIEW 
 
Compared to other clinical laboratory methods, clinical immunohistochemistry (IHC) 
is not fully standardized. IHC daily quality control (QC), which is a part of laboratory 
quality assurance (QA), is not well developed because the required standardized 
positive and negative controls are not yet available. Similarly, proficiency testing (PT) is 
not standardized as a part of external quality assurance (EQA), despite being an 
essential part of inter-laboratory comparison, test calibration, and national QA 
standardization. The aim of QA is to ensure test results are reproducibly accurate. This 
is essential for appropriate diagnosis and patient care. The aim of PT is to demonstrate 
that clinical and diagnostic laboratories perform at the same or comparable level as 
reference laboratories. 
The research described here represents the first attempt to develop standardized 
controls for use in both QC and PT IHC. Breast cancer marker testing by IHC was the 
focus of this research due to the significant clinical implications for patients if test results 
are inaccurate 1.  Test inaccuracy can result from various pre-analytical, analytical, and 
post-analytical factors. In diagnostic IHC, the pre-analytical component is defined as 
human tissue processing that occurs in the operating room and pathology departments, 
until the sample reaches the immunohistochemistry laboratory. The analytical 
component of IHC includes the antigen retrieval (AR) step and the application of 
antibodies and staining agents. The post-analytical component of IHC is the 
interpretation of results. Many expert committees are currently addressing both pre-
analytical and post-analytical components in an ongoing effort to standardize these 
components. However, it is very difficult to truly standardize the analytical component of 
IHC, since methods vary from one laboratory to another and there is continuous effort to 
improve IHC technology and automation. Consequently, current emphasis is being 
placed on the standardization of the expression of IHC results, rather than 
standardization of methods. The standardization of IHC results begins with the 
standardization of the controls used for QC and the samples used in PT. These are 
principal components of EQA for the external monitoring of laboratory performance.  
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1.1 Estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) in breast cancer diagnosis 
1.1.1 Breast cancer 
 
Breast cancer is presently the second leading cause of cancer-related death in 
women and is the most common cancer among women excluding non-melanoma skin 
cancers. According to the American Cancer Society, about 1.3 million women will be 
annually diagnosed with breast cancer worldwide and about 465,000 will die from the 
disease 2. 
 Biologically, breast cancer is an uncontrolled growth of breast cells. Usually breast 
cancer begins in cells of the lobules or ducts. Cancers developing from epithelial tissues 
are designated as carcinomas. There are several histological subtypes of breast 
carcinoma 3. Less commonly, breast cancer can begin in stromal tissues, including the 
fatty and fibrous connective tissues of the breast. Malignant tumors of stromal tissues 
are designated as sarcomas. Cancer occurs as a result of mutations in the genes 
responsible for regulating cell growth. Normally, cells replace themselves through an 
orderly growth process, with healthy new cells taking over as old ones die due to 
apoptosis or “programmed cell death”. Various mechanisms may lead to cancer 
development. Some are related to deregulated growth and proliferation, while others 
affect cell survival 4–6. Mutations in the apoptotic pathway allow a damaged or mutated 
cell to keep dividing uncontrollably, forming both benign and malignant tumors. While 
some cancers are due to an inherited genetic abnormality, many breast cancers have 
no family history. Tumors may arise as a result of an inherited predisposition for cancer 
combined with acquired genetic changes from the aging process 2,3,5. 
Over time, cancer cells can invade nearby healthy breast tissue and make their way 
into the lymph nodes, before moving to other parts of the body. The spreading of cancer 
into lymph nodes or distant organs is called metastasis. “Staging” of breast cancer 
refers to how far the cancer cells have spread beyond the original tumor and includes 
parameters related to tumor size, tumor extension into surrounding organs, and the 
status of metastases.  Detailed description of breast cancer staging is provided in the 
2009 AJCC Cancer Staging Manual 7.  
  3 
1.1.2 Estrogen, progesterone, human epidermal growth factor and breast cancer 
 
Estrogen and progesterone have many important biological functions and travel 
through the bloodstream to receptor sites in both healthy and cancerous cells. Breast-
cell growth stimulation is the most important function of estrogen and progesterone. Like 
normal breast tissue, many breast cancers are hormone-dependent, with estrogen and 
progesterone binding to ER and PR, respectively, thus stimulating cancer growth. 
Breast cancers can be ER-positive (ER+) and PR-positive (PR+) or ER+ only. It is rare 
that breast cancer is PR+ only. ER and PR testing, by IHC, are used to determine if a 
breast cancer expresses ER and/or PR, and will therefore respond to hormonal therapy. 
Women whose cancers are PR+, but ER-, still have about a 10% chance of responding 
to hormonal therapy 2,8. 
The binding of human epidermal growth factor to HER2 initiates cell proliferation and 
indirectly affects programmed cell death. Between 20-25% of breast cancers have 
increased HER2 expression, which is related to more rapid tumor growth, an increase of 
recurrence after surgery and a poor clinical outcome 9. Because of this, HER2 testing is 
critical in determining which cancer patients are eligible for treatment with trastuzumab 
(herceptin), which acts by blocking the binding site of HER2 in tumors. The College of 
American Pathologists (CAP) recommends that HER2 status should be determined for 
all invasive breast cancers 10. HER2 detection can be done by either IHC or fluorescent 
in situ hybridization (FISH). Although both methods are very good, IHC is simpler and 
more cost effective. FISH is generally reserved for cases scored as 2+ by IHC. Such 
tumors may or may not have an amplified HER2 gene and FISH is used for confirmation 
of over-expression 9.  
1.1.3 ER, PR, and HER2 testing and breast cancer diagnosis 
 
Breast cancer survival has improved by approximately 25% over the past two 
decades. This is due, in part, to advances in the understanding of breast cancer 
pathogenesis and therapies targeting ER, PR, and HER2. Highly specific and sensitive 
IHC testing of tumor samples for ER, PR and HER2 forms the basis of stratifying breast 
cancer patients to different treatments. However, these IHC tests have historically 
suffered from poor reproducibility 8,11–16. 
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 Proper ER and PR detection is crucial. The more receptors in a tumor, the better an 
individual’s response will be to hormone therapy. Also, the response to the treatment 
could depend on whether one or both receptors are present in the tumor. For a person 
with ER+/PR+ status, the chance of responding to hormonal therapy is approximately 
70%. With ER+/PR– or ER–/PR+ status, there is approximately a 33% chance of 
responding. If the receptor status is low or unknown, there is about a 10% chance of 
responding 17. Therefore, detection and quantitation of ER and PR needs to be 
accurate. There is considerable published evidence showing that measured levels of 
ER and PR in given samples differ from one testing center to another 7,18–26. Until 
recently, some 30% of participating clinical laboratories failed to detect ER and PR in 
tumors that tested positive in reference laboratories 12. Better method controls for IHC 
EQA and daily QC are required to improve test accuracy.  
ER and PR IHC requires 1% positivity in nuclear staining of tumor cells for a breast 
tumor to be declared ER+ or PR+, resulting in the patient receiving hormonal therapy. 
The same tumor stained for HER2 requires an overall complete membranous staining 
intensity level of 2 out of 3 (on a scale of 0-3+) in order for the patient to be considered 
a valid candidate for Herceptin treatment. These readings can be variable, depending 
on the skill and training of the pathologist, and on the quality of the stain itself 27. 
1.2 IHC  
 
IHC has been used routinely for over three decades in pathology and cytology 
diagnostic laboratories. IHC is used in both Class I and Class II diagnostic testing.  
Class I tests aid in diagnosing disease by the pathologist, while Class II tests also 
provide prognostic and predictive information (e.g., about tumor type) to be applied for 
appropriate stratification of patients for various therapies 10. Standardization of clinical 
IHC lags behind many other clinical laboratory methods. Since IHC is not fully 
standardized, IHC-staining quality can vary greatly between laboratories, depending on 
the expertise of the staff and the methods used 28,29. 
IHC procedures are complex, with many steps and methodologies available to 
achieve the final staining result. Research methods have been adapted for diagnostic 
use to visualize a protein of interest through antigen-antibody interactions. Antibody-
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protein binding properties already in use in immunochemical techniques like western 
blotting and enzyme-linked immunoassays have been applied in IHC to directly observe 
the presence and localization of proteins/epitopes of interest in cells and tissues. 
Samples can be either cytological preparations on slides, or sections of either frozen 
tissue or formalin-fixed paraffin-embedded (FFPE) tissue that have been sectioned with 
a microtome and mounted onto microscope slides. In clinical practice, the great majority 
of IHC tests are performed on FFPE samples. Current attempts are underway to 
standardize terminology and methodology used in the IHC procedure30–35. 
In clinical analysis, an automated immunostaining system is most frequently used for 
IHC staining. These instruments allow for high throughput, using proprietary reagents 
that include a labeled secondary antibody for visual detection. FFPE samples are 
sectioned onto a slide with a microtome before they are prepared for staining with AR, 
usually by heat-induced epitope retrieval (HIER). IHC can be used to visualize the 
presence and location of individual proteins within the tissue and cellular structures of a 
biopsy or tissue sample. Primary antibodies are selected by individual pathologists and 
laboratories for their affinity to proteins (epitopes) that are important for clinical 
diagnosis. A labeled secondary antibody is used to detect the binding of a primary 
antibody to the antigen of interest. Visual identification involves using one of a number 
of different chromagen detection systems. Slides are then dehydrated and mounted with 
a coverslip for viewing and storage 34,36. 
Although expert pathologists interpret staining intensity and antigen localization for 
patient diagnosis according to published literature, the clinical applications of IHC, 
patient tissue processing, IHC protocols, and the interpretation of IHC results, are not 
standardized. This produces varying IHC results in different testing centers37. There is 
also no current published consensus for the techniques and sample selection for IHC 
EQA and internal QC because they are still being defined 37,38. 
1.2.1 Pre-analytical steps – sample collection, fixation and preparation 
1.2.1.1 Fixation and formalin embedding 
 
The pre-analytical component of IHC encompasses tissue processing from 
collection in the operating room or morgue until the processed tissue is ready to be 
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stained in the IHC laboratory. It also includes the so-called “ischemic time” during 
surgery and postsurgical transport to the pathology laboratory, both of which may vary 
greatly. There can also be significant variation in the length of fixation once a 
pathologist has evaluated the specimen. One current recommendation is that optimally 
prepared breast cancer tissue samples should be fixed for a minimum of 8 hr (to a 
maximum of 72 hr) before being embedded in paraffin 39,40. Other sources recommend 
12 hr for minimum fixation 14,20,33. 
Although there are recommendations of fixation within 1 hr of collection, there are 
no binding guidelines for the proper time from excision to fixation for an IHC sample 
39,41,42,43,44. Although optimal fixation periods have been recommended for breast cancer 
markers, there is no evidence that these recommended conditions can be widely 
applied to the more than 200 other clinically important IHC markers 39,41,42. Currently, 
Part I of the Canadian Association of Pathologists (CAP-ACP) IHC Checklist includes a 
general recommendation that all tissues should fixed >12h before IHC testing 45. 
IHC pre-analytical steps vary because tissue samples are collected using numerous 
conditions and methods, depending on the hospital and physician collecting the sample. 
The tissue may be from surgery, biopsy, or autopsy 32,46,47. The period of time between 
collection and proper fixation can vary greatly 48. As a result, biochemical degradation of 
epitopes of interest may occur even before patient samples have been received by 
pathology departments for proper fixation. Recent guidelines for IHC HER2 testing have 
started to address these pre-analytical IHC issues for the first time 33,43,45. Also, many 
hospitals have begun to mandate the monitoring and recording of IHC pre-analytical 
parameters for breast cancer testing 10,21,22,43,45,49.  
Fixatives used in pathology laboratories can also vary. The most common 
preservative used is 10% buffered formalin. It gives results that physicians are most 
familiar with 50. Other non-formalin based fixatives are available, but their reliability and 
accuracy in regular clinical use is not yet fully demonstrated 51. The formalin itself can 
vary in freshness and quality, and the size of the sample will affect how quickly the 
fixative can diffuse through it for preservation. Diffusion itself is not sufficient for proper 
formalin fixation because the biochemical reactions involved in fixation take 
approximately 12 hours to complete 39,41,48,52. Samples preserved for IHC should be 
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segmented into pieces thin enough that the fixative rapidly permeates the entire sample. 
This prevents the damaging effects of tissue ischemia and irrecoverable changes in 
epitopes. Ideally, IHC samples should be resected into small (5-10 mm thick) sections 
and immediately placed into small histology cassettes for fixation and eventual paraffin 
embedding 53 . A volume of between 10:1 and 20:1 of fixative to tissue is recommended 
for rapid fixative permeation of tissue 26,43,54,55. It is also recommended that the time of 
collection and initiation of fixation should be recorded during hospital sample processing 
29,43,56,57. This information will assist pathologists in the identification of improperly 
collected, suspect samples and reduce IHC error due to improper fixation 
One study reported that a minimum of 8 hr of fixation is required for quality IHC 
staining for the detection of ER in breast cancer. However, 24 hr of fixation is the 
approximate optimal fixation time for most samples prior to paraffin embedding 48. 
Fixation of greater than 3 days can interfere with the recovery of some epitopes by 
tissue pretreatment methods, leaving epitopes inaccessible for binding with primary 
antibodies. Many epitopes are shown to be lost after 7 days and unmeasurable after 14 
days 42,54. Other sample pre-treatments, like decalcification, can alter IHC-staining 
quality in an unrecoverable manner 58. The use of decalcified tissues for clinical IHC of 
ER, PR and HER2 is currently not recommended 53,58. The effects of fixation and 
decalcification need to be elucidated for the different IHC epitopes being tested for in 
each tissue type 39,41,54,58–60.  
Following fixation, tissues are dehydrated with ethanol washes and embedded in 
paraffin with an automated tissue processor and embedding system. Paraffin 
embedding became a common part of histological tissue study in the 1950s, for use 
with fluorescent-labeled antibodies 61. Tissue processing and immunostaining 
developed through the 1980s and 1990s in histology 62–64, with automated tissue 
processing standardizing the paraffin embedding procedure 63. Once embedded, the 
tissue can be cut into thin sections (usually 3-5 µm) onto charged glass slides for 
histological staining. The thickness of the sections used in clinical IHC varies greatly 
between testing centers because there is no current standard for section thickness.  
It is important to note that although epitopes appear to be relatively stable once a 
sample is embedded in paraffin, there is evidence that once sections are cut from a 
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block, protein degradation can occur. Studies have shown that if slides are not IHC 
stained within 24-48 hr, they should be stored at a minimum of -20°C to prevent epitope 
degradation 65,66. The best method to preserve epitopes is to cover the sections with 
paraffin and store them in liquid nitrogen 67. Although the proper sectioning and storage 
of slides prior to IHC is very important, this still is not defined or mandated 65,66. 
1.2.1.2 AR methods – HIER 
 
Formalin fixation causes cross-linking between a protein’s structural groups 68. 
Cross-links of arginyl and lysyl peptide bonds and methylene bonds form between 
proteins and this aggregation can block many antibody binding sites. This causes the 
reduction, or complete elimination of, the antibody binding required for IHC staining 31,68. 
Cross-linking will vary with the length of preservation and the strength and quality of the 
formalin solution used 54,55. 
IHC can also be performed on frozen samples, which are sectioned using a 
microtome, with the sections placed onto glass slides. Frozen samples are not fixed 
prior to freezing, and are often used for the preparation of samples in which formalin will 
destroy the epitope of interest. Frozen sections do not contain formalin cross-link 
artefacts, and do not require pre-treatment or HIER before staining. Unfortunately, the 
freezing and thawing of tissues can disrupt tissue morphology, making the localization 
of the IHC staining more difficult to identify and interpret. This prevents wider use of 
frozen tissue in diagnostic IHC. FFPE tissues are more stable than frozen tissues and 
are generally preferred for histological study and diagnosis 36,69 Only a small number of 
clinical IHC tests are currently performed on frozen tissue sections at specialized 
laboratories.  
IHC staining of FFPE samples was variable and inconsistent until AR was 
discovered and pioneered in the 1990s 68,70–72. Initial AR methods used proteolytic 
digestion with trypsin, proteinase K, pronase, pepsin or deoxyribonucleotidase at 
varying concentrations for short periods of time. Not all antigens benefit from enzymatic 
digestion. Extended enzyme digestion may destroy the antigens or the tissue sample 
71,73. Although pepsin and protease are still used for some antibodies in clinical 
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methods, the majority of AR methods combine heat and chemical buffer incubation 
68,71,73–75. Most enzyme-based AR methods are becoming obsolete.  
The most common current method of AR prior to immunostaining is HIER. HIER 
was first demonstrated in 1993 74,76 and allows IHC to be functional with FFPE samples 
in clinical and research settings 47. Manual methods of HIER involve the heating of 
samples in AR solutions to high temperatures (95° - 100°C) via water baths, microwave 
ovens, autoclaves and pressure cookers. Microwaves and digitally calibrated pressure 
cookers are most commonly used in clinical HIER 47,77,78. 
Depending on the tissue and the buffer, the optimal incubation of sample in the AR 
buffer can vary 31,77. Preferred solutions include citrate buffers of pH 6, 9 and 10, and 1 
mM ethylenediaminetetraacetic acid (EDTA) solutions of pH 9-10 68. There is still debate 
as to the optimal HIER buffer for individual proteins 68,77. Research has shown that the 
optimal buffer and buffer pH used for HIER varies from antibody to antibody. Therefore, 
HIER should be optimized for each antibody, in each laboratory, prior to clinical use 
71,72. 
The standardization of AR remains a major issue in reducing IHC-stain variability79. 
Incorrect or irregular AR can affect the quality of IHC staining, so that weakly positive 
samples are missed.  There is still a need to define optimal sample preservation and AR 
methods for IHC 32,80. In an attempt to streamline and optimize AR for clinical IHC, a 
number of automated AR instruments have become commercially available in the last 
five years. These instruments contain a controlled heat source, buffer management and 
humidity control. The implementation of this new technology is slow, due to high cost 
and lengthy validation time 36,80.  
1.2.2 Methodology and stain linearity: analytical and post-analytical IHC 
 
The analytical component of IHC encompasses the protocol used for IHC staining, 
which has a greater potential for standardization than the pre-analytical component of 
IHC. The analytical component cannot be currently standardized because new methods 
and new reagents continue to be developed daily. Any attempt to standardize analytical 
components would also lead to undesirable outcomes, because it would prevent the 
development of better, new antibodies, reagents, and methodologies for IHC detection. 
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Therefore, current efforts are best focused on both the standardization of IHC controls 
and developing the means to objectively monitor IHC performance and standardize IHC 
results with these controls. 
The post-analytical component includes the interpretation of results by pathologists 
or by image analysis (IA). Post-analytical standardization is both expensive and 
complex, but is achievable through national and international consensus and proper 
education 7. Examples of progress in this area include the recently published breast 
marker IHC interpretation/scoring guidelines from the American Society of Clinical 
Oncology (ASCO) and the CAP 7,20. Current guidelines recommend using a Histo-Score 
(HScore), which incorporates both the percentage of positive cells and the intensity of 
staining 81. HScore is discussed in Section 2.6.3.1. 
1.2.2.1 Antibody use, selection and IHC method optimization 
 
Purification of antibodies for research in the 1920s allowed further study of their 
structure and binding qualities 82,83. By 1967, there were published methods for the 
preparation and enzyme labeling of antibodies for use in antigen localization 84.  In 
1970, Sternberger et al 85 published a paper specifically on the use and fluorescent 
labeling of antibodies that initiated the field of immunohistopathology. Early methods for 
fluorescent antibody labeling in histopathology were published in 1978 86. Peroxidase 
and avidin-biotin labeling methods were developed to produce stable, long-lasting 
antibody labels. These non-fluorescently labeled antibodies are currently more 
commonly used with FFPE tissues in most applications 36,70. 
Antibodies for human proteins/epitopes are primarily raised in mice, rabbits and 
goats. Initially, only polyclonal antibodies were made. Polyclonal antibodies recognize 
multiple epitopes on a single molecule. While this may increase staining, polyclonal 
antibodies are more likely to react non-specifically. The development of purified 
monoclonal antibodies increased staining accuracy in IHC and other immunoassay 
techniques due to their purity and specificity. Monoclonal antibodies are a 
homogeneous population of immunoglobulin directed against a single epitope, and far 
more specific for use in IHC staining 36,87.  
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The use of monoclonal antibodies, combined with a blocking step, has removed 
most background staining from IHC and increased its specificity 87. However, many 
excellent quality polyclonal antibodies continue to be used in both research and clinical 
applications. Different antibodies produced to the same protein may have different 
binding efficiencies because they bind to different parts of the antigen of interest. The 
American Food and Drug Association (FDA) have approved a number of monoclonal 
antibodies for clinical use; however, the use of specific antibodies, or antibody clones, is 
not mandated.  
IHC-stain quality can vary with the antibody used 36,37,47,49,72,87–89. Different 
antibodies can give very different staining results depending on the epitope they detect 
90,91. The dilution of antibody used in IHC varies depending on tissue fixation, AR 
methods, and reagents used 91. Therefore, it is important, in routine practice, to know 
the optimal IHC conditions for each tissue type and antibody 46,92. Currently, each 
laboratory may choose their own antibody and optimize conditions for it, leading to a 
wide variation in stain quality between laboratories 32,93. 
1.2.2.2 Analytical parameters of IHC automation and IHC detection systems 
 
A large number of detection methods and automated instruments are available for 
clinical IHC 47. Each manufacturer sells reagents they recommend for use with their 
instruments and detection systems. Each laboratory must determine their own optimal 
protocols for each epitope they measure with IHC. These protocols vary because each 
laboratory has a different knowledge of what these optimal IHC protocols should be. 
Antibody binding in IHC is visualized via a labeling compound. The chromagen can 
be directly linked to the primary antibody or to a secondary antibody that will bind to the 
primary antibody 36,47,72. The chromagen can also be linked to a polymer molecule 
which is bound to a secondary antibody 36. Because fluorescent labeling is temporary, 
clinical IHC usually involves a stable chromagen or particulate label. Common 
chromagen systems include diaminobenzidine (DAB, a brown color), 3-amino-9-ethyl-
carbazole (a red or brown color, depending on processing), Hanker Yates reagent, fast 
blue, fast red and nitroblue tetrazoleum 36,72. Using multiple primary antibodies together 
with differently labeled secondary antibodies allows for dual staining on a single slide 
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36,94. IHC positive staining can be better identified when unstained tissue is 
counterstained with hematoxyllin. This positive staining is localized in different cell 
compartments (nuclear, cytoplasmic, membranous, extracellular, or any combination of 
these), depending on the biological distribution of the epitope of interest. 
Horseradish peroxidase (HRP)-DAB staining is the most commonly used IHC 
detection system, with the peroxidase bound to the antibody or polymer 36. Osmification 
of DAB reagent added to the slide produces an intense brown color that is alcohol 
resistant and resistant to fading. Because DAB is alcohol resistant, it can be used with a 
wide variety of FFPE samples. DAB is the most frequently used chromagen because it 
has a high signal-to-noise ratio and produces a specific morphological visualization47.  
Efficient, commercial protocols and chromagens have been paired with automated 
staining machines for clinical use by Ventana and Dako 78,87,95. These instruments use 
batch-controlled reagents, with specially designed secondary antibodies. These special 
secondary antibodies are bound to a polymer which has a large number of HRP 
molecules attached to it 36. This antibody:polymer construct provides a large number of 
HRP molecules for a chromagen to react with, thus increasing IHC-stain intensity. This 
Automation and reagent consistency improves test reproducibility 36,79. 
In its early stages, IHC lacked sensitivity and specificity, largely due to problems 
with reproducibility 87,96. As techniques have become more standardized, clinical utility 
of IHC has increased 47,87. Greater attention is currently being given to antibody 
selection and optimization of the various steps in the IHC-stain process 26,72. Many 
parameters must be considered during this complicated optimization process 46,47. A 
suggested definition of these optimization parameters was recently provided by the 
Canadian Association of Pathologists National Standards Committee for IHC 45. 
1.2.2.3 Non-linearity of IHC 
 
Due to the multilayered process of IHC staining, the final staining intensity has a 
linear relationship with the concentration of the stained epitopes only up to a certain 
staining intensity. This linear range is clearly visible in other immunoassay applications 
such as enzyme-linked immunoabsorbant assays97. In practical application (unless 
mandated otherwise), IHC intensity is calibrated so that staining is as intense as 
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possible without introducing false-positive or background staining. When IHC linearity is 
considered, one must consider the effects of detection systems, which are based on 
signal amplification. Generally, current clinically applied IHC methods are intrinsically 
non-linear. However, there are some special conditions in which linearity may apply. In 
samples with low to moderate expression levels of the epitope/analyte of interest, IHC 
staining intensity appears to increase in a linear fashion within a certain range, with the 
overall staining appearing to be logarithmic in relation to epitope concentration and 
antibody dilution98. Similarly, higher antibody dilutions, which will result in decreased 
test sensitivity, may also produce a linear stain result 98. While IHC allows effective 
measurement of the presence of an antigen, it is difficult to use IHC in a strictly 
quantitative or qualitative manner when interpreted manually, due to the lack of 
standardization and published guidelines 28. Intensely staining tissues allow for simple 
identification of positive results, but these tissues have less measurable stain variation 
between samples. This is due to the inability of the human eye to discern small stain 
intensity differences at higher cumulative stain intensities. The stain signal produced 
may be oversaturated for lower levels of the epitope of interest. Although higher 
dilutions of primary antibody may produce better linearity, clinical applications of such 
dilutions are not recommended, since many low-expressing tissues would be 
completely negative with this approach. The application of IA to IHC must take this 
information into account when used to monitor and calibrate IHC methods. 
Because IHC allows the observation of protein expression within the cell and tissue 
itself, it yields a greater understanding of the disease process. To use IHC in a 
quantitative manner requires that current pre-analytical, analytical and post-analytical 
problems are addressed. Only then will IHC approach the level of accuracy and 
precision of other biochemical and immunoassays currently used for patient diagnoses 
33,58,72. The quantitative use of IHC on FFPE tissues is now possible because of largely 
standardized and optimized HIER methods, although the lack of stain linearity remains 
an issue 99,100,101 .  
1.2.2.4 Class II IHC tests  
 
Class II IHC tests are IHC tests from which results are interpreted by pathologists 
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for use by physicians who are treating patients. Physicians use Class II IHC test results 
to stratify patients for appropriate therapies. Class II tests are either predictive of a 
patient’s response to a particular drug, or prognostic by giving information about a 
patient’s outcome in particular clinical setting 33,58,72,102. Unlike IHC, most other Class II 
clinical laboratory results are liquid-based with optimal control systems.  
1.3 PT and daily QC 
 
The quality of clinical laboratory service is monitored with a combination of in-
laboratory QA, standard operating procedures and EQA programs. The principal goal of 
EQA is to evaluate laboratory results and observe their agreement to a reference 
source, reference laboratory or designated reference result. PT is an assessment of 
analytical performance in comparison to peer performance or a reference system103. 
Some EQA programs provide PT and enable participants to validate their IHC protocols 
or monitor their calibration. There is no current standardization of PT and the design of 
PT methods varies widely between the different PT programs 10,33,49,59. 
Daily QC includes the use of calibration standards and acceptable ranges, which 
are available for routinely measured analytes for most laboratory tests. Standards are 
reflected in the controls designed for daily use. Unfortunately, both calibration standards 
and acceptable clinical ranges are not precisely defined for clinical IHC tests. It is also 
not possible to define IHC standards from currently used, positive IHC controls33. This is 
in stark contrast to other optimized clinical tests (like glucose measurement), which are 
supported by standardized controls and standardized interpretation of results.  
Ideally, controls monitor instrument/method performance and aid in the interpretation 
of results. Good controls are stable, quantifiable, universally available, and ideally 
inexhaustible and affordable. Standards and controls should as closely resemble the 
sample being measured as possible 103. Consequently, the majority of current clinical 
IHC controls are prepared from previously tested patient samples. In order to measure 
method stain quality and consistency, tissue sections are selected that are both positive 
(to confirm staining) and negative (to rule out false/nonspecific staining) 37,103,104.  
1.3.1 PT 
 
PT programs periodically send specimens (which are primarily human tissue) to a 
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group of participating laboratories for analysis. PT programs then compare the 
participant results with a designated “gold standard/reference result”. The choice of the 
reference result is up to the discretion of the EQA program. Results are presented in a 
format which compares the results of each participating laboratory with the results of 
their peers105. In IHC EQA, all participating laboratories receive an unstained slide of 
test sample(s). Each laboratory tests the samples and is usually required to provide an 
interpretation of their own results. The stained slides are typically returned to the EQA 
program for assessment and final scoring. Most EQA programs issue a performance 
report for each participating laboratory. This report may contain a comparison of the 
participating laboratory to other participating laboratories and a reference laboratory or 
result104.  
PT is very valuable and informative, but it is only a part of a total QA program. Total 
QA is the sum of all measures in an entire system to ensure quality testing. PT 
compares participants to the most relevant and accurate instrument/reagent 
combinations to assess performance 104,105. However, this is not sufficient for QA, since 
laboratory QA includes all measurements that ensure quality laboratory testing including 
test validation, staff training and competency assessment, standardization of operating 
procedures, and equipment maintenance. Good QA will address method performance 
and provide training and assistance for improvement 106. Unacceptable PT results need 
to be further investigated to identify whether they reflect real errors in clinical testing. If 
errors are found, their root cause needs to be documented, so that corrective action can 
be taken 104,107. In clinical EQA, the quality of the control used is essential in evaluating 
laboratory methodology and instrumentation. It has been argued that the closer the 
EQA sample for PT is to a “normal” patient, the more useful it is 30,104.  
EQA employs PT to evaluate clinical laboratories. EQA has benefits that cannot be 
achieved by in-laboratory quality programs alone. EQA allows for "comparison of 
performance and results, serves as an early warning system for problems, identifies 
systemic kit problems, provides objective evidence of laboratory quality, indicates where 
to direct improvement methods and identifies training needs”108. EQA programs are 
particularly effective when they combine the evaluation of PT results with a supportive 
consultation when PT results are not acceptable. Such programs positively affect the 
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quality of care available in hospitals by improving the quality diagnostic laboratory 
testing 107. 
It is clear that the lack of consistent, reproducible control material for IHC hinders 
the optimization of current daily QA and EQA. Both human tumour tissues and cell lines 
can be used for this purpose. However, further study is required to identify what optimal 
samples are for use in PT.  
1.3.2 Levey Jennings plots in QA 
 
Walter Shewhart proposed QC charts in 1931109 as a way to monitor quality in 
manufacturing operations 110. His idea111 was modified for use as a clinical laboratory 
QA system by Levey and Jennings in 1950112. Westgard further optimized the use of 
Levey-Jennings charts with the creation of his "Westgard Rules" for QC charts 113,114. 
His rules dictate statistical guidelines for when controls and samples in an assay must 
be rejected and repeated when using these QC charts 115–117. With the aid of these 
rules, clinical laboratories use QC charts to monitor both accuracy and precision in their 
laboratory methods. This system is usually applied to liquid-based tests and is not 
currently applied to cell-based assays like immunohistochemistry or flow cytometry.  
To create and maintain a Levey-Jennings QC Chart, a minimum of 20 readings of 
the same standard or control should be consecutively measured on the same 
instrument using the same method and reagents. The mean value of these 
measurements, as well as the standard deviation (SD) from the mean is then 
calculated. The mean, ± 2 SD and ± 3 SD are then plotted parallel to the X-axis on the 
chart. New control readings are recorded using this chart as a reference. New recorded 
values should be within 2 SD from the mean and rejected when they are outside of ± 3 
SD from the mean. Out of range controls and samples must be repeated. The more 
precise the test method, the smaller the ± 3 SD ranges will be112. These charts are 
primarily used for internal QA and trend monitoring. QC charts are especially useful 
when applied during the set-up of new laboratory methods to monitor and confirm 
method accuracy and precision 113,115,118,119. It is possible that similar QC charts could 
be applied for laboratory-to-laboratory comparison in EQA programs, or for monitoring 
  17 
trends from one PT run to another with the same analyte. None of the current EQA 
programs or in-laboratory QA methods use QC charts for clinical IHC 45,49,102 
1.3.3 Standardization of QC in clinical IHC 
 
Class I and Class II IHC tests, due to how their results are used, require different 
approaches to QA. All IHC tests are in need of standardized control materials. Such 
controls could be used in quantitative IHC testing for Class II markers, including ER, PR 
and HER2 tests. Unfortunately, these standardized, quantitative positive and negative 
controls are not yet available for clinical IHC. Peptide IHC controls may be suitable, but 
not ideal, for this purpose 101,120–122.  
For IHC, it is currently recommended that tissues of known positive and negative 
expression are sectioned onto the slide containing clinical samples for direct 
comparison 123. Variability between each unique control specimen and within each 
specimen block remains a problem10. Each tissue control block is unique, with varying 
levels of antigen expression throughout the depth of each block due to biological 
variation. Biological variation is usually larger in tumor samples than in benign, 
histologically normal tissues. This prevents the use of current IHC controls as 
quantitative controls 10,99,100. While attempts to use tissue microarrays (TMAs) 
containing multiple tumor and normal tissues are useful 124, the number and types of 
relevant samples required to accurately test for IHC performance characteristics for ER, 
PR and HER2 are still not known 10,33,40,125,126. 
An IHC positive control or “reagent control” shows that the system/methods used for 
the test work as expected. A calibration control is a standard of known value that allows 
the quantification of a set of known standards. Test results are then compared to these 
standards and quantified via this comparison 127,128. Very few calibration controls are 
currently available for clinical IHC. These include commercially available cell line 
controls for HER2 129 and a small number of peptide controls 101,130. The purpose of an 
IHC negative control is to display how the experiment works in the absence of the 
measured epitope and provide a baseline value for comparison to ensure experimental 
consistency 127,128. Therefore, it is not possible to standardize a method without 
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standardized positive controls or references; standardization of a protocol is 
meaningless without control standardization 117,131–133.  
Manufactured peptide control slides were recently developed in the United States 
and were shown to be stable, reproducible, and sensitive in monitoring IHC analytical 
components120,130. Purified peptide controls are suitable to monitor the performance of 
automated staining instruments to ensure that the equipment and reagents are 
performing at the same level of calibration from one run to another101,121. However, this 
purified protein is not an accurate reflection of naturally occurring protein expression in 
preserved tissue samples because these proteins have not undergone tissue sample 
processing. Peptide controls were used successfully in 2006 in a CAP PT run for HER2 
130, but have never been used clinically. There is still debate regarding whether peptide 
controls can be used as clinical IHC calibration controls and how accurately they will 
monitor system performance 120. In addition to this, peptide controls are very expensive 
and their routine clinical use is unlikely due to their price.  
1.3.3.1 Canadian IHC QA 
 
Health is under provincial jurisdiction in Canada. As a result, histology laboratories 
are not accredited in all provinces and there are no national standards for IHC QA/QC 
and no national mandated EQA IHC program 10. The Ontario Quality Management 
Program for Laboratory Services carries out provincial testing and monitoring in many 
laboratory disciplines134. Unfortunately their ER, PR and HER2 IHC PT methods are 
only applied on a provincial level 10,19,135.  
The Canadian IHC Quality Control (cIQc) Program was established in 2009 to 
provide a QC/QA program for IHC testing in Canada. The cIQc Program is an 
academically initiated, anonymous, voluntary EQA program for Canadian diagnostic 
IHC laboratories. Test slides are cut from TMAs created by the cIQc Program from 
known tissues. Stained slides are scored (self-assessed) and these results are reported 
through an online TMA-Scoring program for an instant comparison to a reference 
laboratory result. The slides are also returned to the cIQc Program along with the 
protocols used for staining. Laboratory performance is evaluated by a group of expert 
cIQc assessors102. Both self-assessment and expert-assessment results are posted for 
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analysis, together with the different protocols used. Code numbers are used for 
laboratory identification since participation is anonymous.   Laboratories with poor 
results can consult with cIQc panel experts to optimize their IHC methods. Additional 
cIQc slides are then made available to laboratories to test modified protocols.  
The cIQc Program is a provider of PT, but it has no regulatory functions. One of the 
largest contributions of the cIQc Program is that de-identified results of participating and 
reference laboratories are made available as an open-access service on the cIQc 
website to provide an open, independent forum for discussion and education, and an 
evidence-based standardization of IHC testing 10,33. 
1.4 IA 
 
The use of digital IA to interpret IHC staining is a relatively new approach to dealing 
with assessment inconsistency. IA is the application of computer algorithms to measure 
desired aspects of a white balanced digital image136–138. When applied to IHC, IA can 
reduce human error in IHC interpretation 32,139. Recently, digital IA has been compared 
to expert assessment of IHC staining as a diagnostic tool in pathology and in QA. IA 
evaluation of IHC of ER, PR and HER2 is performed comparatively to pathologist 
scoring of clinical samples in these studies 139–141. IA has recently been FDA-approved 
for ER, PR and HER2 IHC interpretation under specific conditions 139,142. IA for IHC 
interpretation is best applied to an area of interest selected by an expert pathologist, 
who will select only tumor tissue to be interpreted by IA. Uniform areas with abundant 
tumor are easier to evaluate with IA than tissues with a combination of benign and 
malignant tissue or scant tumor tissue. IA erroneously analyzes the both normal and 
tumor cells together when the area of analysis is not preselected. For these reasons, 
unsupervised IA of IHC results is not clinically acceptable. 
1.4.1 Development 
 
By 1850, microscopes were high enough in quality for reliable observation of 
cellular structures. In 1858, the first textbook of histopathology was published. Formalin 
fixation of tissues for extended study became a more common practice, and is now the 
standard fixation method used. Histology and IHC expanded the use of microscopy in 
the medical field35. The application of IHC in personalized medicine is known as 
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“morphoproteomics” 143–145.  
As film photography advanced, adaptors were developed so that cameras could 
capture microscopic images. The first digital microscopy system was described in 1997 
at the University of Maryland and the Pathology Department of Johns Hopkins Hospital 
146. Image quality increased to the point that a digital image is now equal in quality to a 
microscopic image viewed with the human eye. Digital image capture was first clinically 
applied to radiology images and has become commonplace in electron microscopy and 
pathology microscopy35,147.   
Digital pathology involves the scanning of entire histopathology slides as digital 
images that are interpretable on a computer screen with data management software. 
The IA system can be automated and combined with internet accessibility and 
annotations for education and long distance, expert consultation. Modern pathology 
standards of optical microscopy have expanded to include digital microscopy. There are 
currently some 30 commercially available imaging devices varying in image 
magnification, scanning speed, user friendliness and diagnostic functionality 148. 
Validation studies on the application of IA in pathology show generally good agreement 
between glass slide and digital diagnosis 147,149,150. Companies like Aperio and Leica 
have paired with microscope manufacturers to offer entire digital pathology packages 
that combine a microscope with computerized image acquisition and analysis 148,150,151. 
There is great potential to improve patient diagnosis through efficient long-distance 
consultation between medical experts. However, better internet data security is required 
before this can occur. 
Scan time is prohibitively slow on some IA systems. Also, the image from a scanned 
20X or 40X slide is a large file requiring a large amount of storage space. Because of 
this, digital IA is more commonly used in medical education, where preselected “ideal” 
slides are used for lectures and image study banks. Currently, 33% of American 
medical schools teach using digital microscopy and this number is projected to increase 
to 50% within five years 149,150. However, advances in technology are promising more 
rapid scanning of slides and more efficient image compression to reduce image size for 
storage and transmission.  
IA is widely used in research to optimize an image and analyze stain intensity with 
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pixel counting software138,152 Each image is scanned and appropriate areas screened 
for IA analysis. Each individual data file is exported and combined into a master file for 
sorting and statistical analysis.  
1.4.2 Algorithms and automated IA with IHC 
 
Advanced digital imaging systems pair the capture of whole slide digital images with 
diagnosis-aiding IA software. The Aperio Scanscope CS system (used in this project), 
incorporates computer algorithms that can recognize cellular structures and measure 
intensities of pre-calibrated colours in an image, effectively allowing the computer to 
“grade” the staining intensity of an image as a pathologist would 142. This has 
advantages over manual pathology by removing observer bias and allowing calibrated, 
consistent diagnosis. When combined with reproducible stain quality, IHC IA can 
measure differences in staining intensity that are not distinguishable by the human eye 
148,150,151.  
For optimal IA, it is important to capture the image for analysis with a three charge-
coupled device (CCD) camera which measures red, green and blue (RGB) separately. 
Older, single CCD cameras simulate all colors simultaneously, which may create 
measurable image artefacts. Because of the complexity of three CCD images, it is 
important that IA analysis of multiple samples is applied to images obtained from the 
same calibrated instrument. This removes subtle alterations due to light source, colour 
temperature, colour-correction and unique circuitry to optimize image quality. If this is 
not done, small differences could greatly affect IA measurement of faintly stained 
samples, creating erroneous results 32. 
When properly applied, IA is unbiased and consistent. For experimental IA of stain 
intensity, samples are processed together with a known, quantified control sample. This 
allows correction for small changes in staining intensity between different experiments. 
The ideal reference is quantified and can be used to calibrate quantifying algorithms. 
Unfortunately, tissue heterogeneity prevents identical IHC controls. As a result, IA of 
IHC cannot be as stringently applied for quantitative measurement. To compensate for 
this in research applications, change in overall intensity is measured by averaging the 
measured intensity of a number of different control samples. By this method, only 
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overall increases or decreases in staining can be observed. This is why IA is only used 
in the semi-quantitative interpretation of clinical IHC stains150. True quantification of IHC 
results with IA has limited value with current methods and controls.153.  
1.5 Reverse transcription, quantitative real-time polymerase chain reaction (RT-
qPCR) analysis 
 
RT-qPCR was pioneered in the 1990s and has been used in research since 2000 
154–156. RT-qPCR is currently used to quantify gene expression in samples of cells or 
tissues 157–160. The amount of protein expressed in a sample is measured indirectly by 
converting the sample’s mRNA into cDNA, which can then be amplified and quantified 
via PCR. An mRNA strand is reverse transcribed into its complimentary DNA strand 
using the enzyme reverse transcriptase. The DNA is then amplified using PCR. This 
allows a measure of gene expression, which is often assumed to reflect or correlate with 
the amount of protein expressed in the sample 155. In this way, RT-qPCR provides 
additional, indirect measure/information about the transcription of genes within a 
sample. A positive correlation of RT-qPCR data with IHC-stain results shows that both 
mRNA and translated proteins/epitopes in the FFPE samples are relatively stable. It 
should be noted that the decay kinetics of mRNA and proteins due to the IHC procedure 
are not yet known for FFPE samples 155,157,158,160.  
1.6 Research objectives 
 
Premade, affordable, calibrated controls are currently not available for clinical use in 
IHC or for PT by EQA programs. This work explores different approaches to develop 
calibrated, standardized controls for diagnostic IHC QC and for EQA PT that could be 
affordable in daily practice. It also evaluated feasibility of IA for interpretation of control 
results in both types of applications.   
1.6.1 Hypothesis 1: IA can be used in diagnostic IHC PT for EQA to rank 
individual laboratory performance, with respect to reference laboratory 
performance, using HScore and Laboratory Score: Reference Score Ratio 
(LSRSR). 
 
Current cIQc EQA results are evaluated by a panel of pathologists. These 
evaluation results are used to calculate the sensitivity, specificity and the percentage of 
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correctly stained tissue cores for each laboratory. Cohen’s Kappa values (κ) are 
calculated to evaluate for interlaboratory agreement of the participating laboratories 
versus the designated reference results. Acceptable Laboratories are ≥ 90% in 
agreement with cIQc reference results, with κ ≥ 0.8 (near perfect agreement) 161. In this 
study, both IA and expert assessment were applied to evaluate the results of the PT by 
the cIQc. This study assessed whether relative scoring ratios like HScore or LSRSR can 
be used to standardize ER, PR and HER2 IHC instead of absolute pass/fail 
measurements. IA-based ratios may provide more useful information from a smaller 
number of samples than current TMA expert assessment methods.  
1.6.2 Hypothesis 2: Cell line-based calibration models are applicable in IHC PT 
and can be used in place of current TMA models. 
 
Calibration controls for an individual IHC laboratory method should be as similar as 
possible to the samples measured with these methods. Ideally, the processing of 
controls is identical to the processing of patient samples, using the same fixatives and 
fixation times. Formalin fixation (with or without decalcification), paraffin embedding and 
HIER are major components of tissue processing before it is analyzed by IHC 101. To 
improve current EQA and PT methods, a cell line microarray (CLMA) was created 
containing nine human breast cancer cell lines. This CLMA was compared to currently 
used TMA calibration models made from human tumor samples in ER, PR and HER2 
IHC PT. This work compares the performance of cell line samples to the performance of 
human tissue samples when used in IHC PT. IA was used to evaluate the performance 
of these samples.  
1.6.3 Hypothesis 3: Cell line-based calibration models are applicable as daily 
positive controls for Class II IHC tests and can be monitored by IA with Levey 
Jennings-QC charts. 
 
QC chart analysis has traditionally been applied to liquid-based laboratory testing.  
QC chart analysis has not, to date, been applied in diagnostic IHC laboratories. This 
work explores the feasibility of using IA to monitor and evaluate current clinical controls 
for ER, PR and HER 2 IHC made from human tumor and benign tissues. Current 
human, tumor-based controls from four major Canadian academic laboratories (that are 
reference laboratories for the cIQc Program) were analyzed with IA. New cell-line based 
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controls were also analyzed with IA. Levey Jennings-QC charts from tissue-based 
controls were evaluated. QC charts from tissue-based controls were compared to QC 
charts from cell-line based controls for ER, PR and HER2 IHC. 
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2.0 MATERIALS AND METHODS 
 
A detailed list of chemicals and reagents is included in Appendix A. A detailed list of 
solution and medium recipes is included in Appendix B. A detailed list of instruments 
and relevant materials used is included in Appendix C. A detailed list of computer 
programs used is included in Appendix D.   
2.1 Cell culture 
 
Nine human breast cell lines were selected for inclusion in the breast marker 
CLMAs: AU-565, BT-474, HBL-100, HS-578T, MCF-7, MDA-MB-231, MDA-MB-435, 
SK-BR-3, and T47D. These cell lines have been demonstrated to express varying levels 
of ER, PR and HER2 162–164. All cell lines are available from the American Tissue Type 
Collection (ATTC) cell repository in Manassas, VA, in the United States. Cell lines were 
graciously gifted by Dr. Anderson, Dr. Carlsen, Dr. Lukong and Dr. Decoteau at the 
University of Saskatchewan, Saskatoon, SK.  
All nine cell lines were adherent, growing in a monolayer attached to the bottom of a 
specially treated culture plate or flask. Cells were cultured in T25 (25 cm2) and T75 (75 
cm2) vented culture flasks, with appropriate medium, in a 37 °C humidified growth 
incubator containing 5% CO2.  All media were supplemented with fetal bovine serum 
(FBS), penicillin and streptomycin. Some medium formulations had additional growth 
factors. All manipulations and medium preparations were performed in the sterile 
environment of a biosafety cabinet using aseptic technique and sterile pipettes. A brief 
summary of cell culture method is described below. 
Cell lines were stored frozen in liquid nitrogen tanks in medium containing 10% (v/v) 
FBS and 5% (v/v) dimethylsulfoxide. Using aseptic technique, 1 mL volumes of frozen 
cells were thawed in a 37 °C water bath and gently transferred into a T25 flask 
containing 8 mL of pre-warmed medium. Following overnight incubation, culture 
medium was gently aspirated and replaced with fresh, pre-warmed medium. Healthy 
cell cultures were passaged a minimum of two times after thawing, before being used, 
so there was no residual affect remaining from being frozen. Cells were then 
subcultured into larger T75 flasks to grow up the large quantity of cells required. Healthy 
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cells were also refrozen for future use as required. Following initial storage, a vial of 
cells from each frozen culture batch were thawed and cultured to confirm viability. 
Adherent cell lines grow to confluency cover the bottom of the flasks and cultures 
will cease growth and die once they reach confluency if they are not subcultured. To 
passage cells into new flasks, the culture medium was aspirated from the flasks with 
sterile pipettes. The cells were gently rinsed with 5 mL of pre-warmed, sterile, calcium- 
and magnesium-free Dulbecco’s phosphate buffered saline (D-PBS). D-PBS was 
removed and 3 mL of sterile, pre-warmed 0.25 mM trypsin-EDTA solution was added. 
After a 1 min incubation at room temperature, all liquid was removed and the flasks of 
cells were placed in the CO2 incubator at 37 °C for 2 to 5 min until cells rounded up and 
detached from the bottom of the flask. Then 6 mL of fresh, pre-warmed medium was 
pipetted into the flasks and the cells were slowly pipetted up and down. This was done 
to break up clumped cells and create a uniform seeding solution for sub-culturing new 
flasks. A portion of this cell solution was placed in a new T75 flask and brought to a final 
total volume of 20 mL with pre-warmed medium. Each cell line was diluted according to 
their optimal subculture dilution. Flasks were placed back into the 37°C CO2 incubator. 
Medium was exchanged every 48 hr until cells again reached a sub-culturing density. 
This was repeated until sufficient cells were grown to make cell line blocks. To maintain 
culture robustness, cells were only passaged 20 times. Table B1, in Appendix B, shows 
the optimal medium and passage conditions for each cell line used. 
Cells were cultured by a secondary method to confirm that IHC staining was 
observed in non-paraffin embedded cell samples. This was done in two ways. Cell lines 
were cultured directly onto glass slides for IHC staining using EZ-Slides. EZ-Slides have 
four or eight sterile, separate culture chambers per slide. Cell lines were grown on EZ-
Slides with the same methods, medium and growth conditions as in flasks. When cell 
lines reached confluency, culture medium was poured off and the cell chambers 
removed form the slide according to manufacturer instructions. Cells that remained 
attached to the slides were fixed for IHC staining, as described in Section 2.3.  
Three cell lines (AU-565, MDA-MB-231, SKBR3) adhered poorly to EZ-Slides and 
washed off during the IHC-staining process. These cells were cultured with standard 
methods in T25 flasks and collected in the same manner as for cell pellets (described in 
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Section 2.2.1). The D-PBS-rinsed cells were spun down onto positively charged glass 
slides using specialized funnel filters and a Cytospin 4 centrifuge. A total of 2 X 106 cells 
were spun onto slides at 2000 RPM for 3 min. Cells were then fixed for IHC staining as 
described in Section 2.3. 
2.2 FFPE cell blocks 
2.2.1 Creation of cell pellets  
 
It is ideal to have control material that is directly comparable to patient tissue 
samples regarding tissue (or cell line sample) processing, including the type of fixative, 
time of fixation, and embedding medium and methods of embedding. Cell lines were 
collected and made into thrombin pellets, as described briefly below. This step was 
done in order to aggregate the cell lines in clotted plasma and create a sample that 
could be processed with the same methods as patient tissue samples. Following this, 
the cell pellets were fixed in 10% buffered formalin and embedded in paraffin in the 
same manner as patient tissue samples at Saskatoon City Hospital (SCH) of the 
Saskatoon Health Region (SHR), also as described below.  
Trypsin, which is used to subculture adherent cells, can cause minor changes to 
cellular morphology during the detachment of cells from the culture vessel 165. Because 
of this, trypsin was not used when harvesting cells. EDTA alone causes adherent cells 
to detach as a layer rather than rounding up individually. Removal of cells at passage 
density (as per Table B1) was carried using sterile D-PBS containing 2 mM EDTA. A 
brief description of this method is described below. Growth medium was removed from 
the flasks. Cells were rinsed with 10 mL pre-warmed, sterile D-PBS. This was removed 
and 10 mL of room temperature, sterile D-PBS + EDTA was added to the culture flask. 
Flasks were incubated in the CO2 incubator at 37°C for 3 - 5 min until cells detached. 
Flasks were tapped firmly twice on the laboratory bench to completely detach the cells 
into solution. Cells were gently pipetted up and down twice with a 10 mL sterile pipette 
to break up the cellular monolayer and the re-suspension was then placed into sterile 15 
mL centrifuge tubes. Cells were pelleted by centrifugation at low speed (1000 RPM) for 
2 min. The EDTA solution was removed and cells were rinsed by resuspension in sterile 
D-PBS and centrifuged again. Before centrifugation, a sample was taken to quantify the 
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cells with a haemocytometer according to standard methods165 (Section 2.2.2). The D-
PBS was poured off and a final D-PBS wash was carried out in the same manner. Cells 
were combined or divided at this stage to obtain the required number of cells per pellet 
(See section 2.2.2) in each tube. The final rinse solution was poured off and a P-100 
Gilson pipettor was used to carefully remove any remaining D-PBS.  
The cells were resuspended in 150 µL of human AB plasma with gentle finger 
vortexing. An equal amount of thrombin solution from the Beckman Coulter HemosIL 
Thrombin Time kit was added. The tube was finger vortexed for 10 sec and placed in a 
rack for 3-5 min at room temperature to allow a firm clot to form. Then 5 mL of 10% 
buffered formalin solution was added. Inversion was used to loosen the clot from the 
tube for complete fixation. 
2.2.2 Cell pellet optimization 
 
Due to the costly nature of cell culture, it was important to determine the appropriate 
number of cells required for a diagnostically useful cell pellet. A number of blocks were 
created with different cell concentrations. Once cells were harvested, rinsed and 
resuspended in D-PBS, they were counted in a Springline haemocytometer, by using a 
mixture of 100 µL of cell solution with 100 µL of 0.5% trypan blue. 165.  
Once counted, the volume required for a specific number of cells in each cell block 
was suspended in a thrombin pellet. Thrombin pellets were fixed, embedded, sectioned 
and IHC-stained. Stained slides were examined manually to ensure proper dispersion of 
the cells in the pellet. Slides were also scanned and analyzed by digital IA to ensure the 
IA software could correctly measure staining in cell pellet blocks. The final thrombin cell 
pellets used for IHC and IA contained 2.0 X 107 cells in a 300 µL volume. This number 
of cells was present in two 95% confluent T75 flasks. For cells harvested at 70-75% 
confluency, three T75 flasks were required, while cells harvested at 50% confluency 
required six T75 flasks to be used.  
2.3 Fixation and embedding of tissue and cells for histological staining 
 
Fixation is used to prevent post-mortem decomposition, thus preserving structure. 
Fixation prevents autolysis and prevents cells from changing their volume or shape. As 
previously discussed in Section 1.2.1.1, there are optimal times for fixation of 
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specimens in buffered formalin before the samples are further processed and 
embedded. 
Cells pellets were fixed overnight (12-14 hr) in 10% buffered formalin. Clinical tissue 
samples are fixed for 8-48 hr in 10% buffered formalin. After fixation, pellets were 
placed into pre-labelled plastic cassettes. Smaller biopsies, tissue samples, and cell 
pellets are placed inside a folded piece of histological-grade tissue paper before being 
placed inside the cassette to prevent sample loss during processing. The thrombin cell 
pellets form in a conical bottom tube, so the pointed tips of the cell pellet were trimmed 
off the narrow end of the pellet with a sterile razor blade. This tip and the remaining 
disc-shaped clot were placed horizontally within the paper and cassette to create the 
largest diameter sample possible. In this way, the sample spans the entire depth of the 
finished paraffin block. This allows the maximum number of samples cores per fixed cell 
pellet and sections per finished block. Up to three cell pellets were placed in each 
cassette to optimize cost and labour. Cassettes were placed back into 10% buffered 
formalin until processing later the same day. 
Samples were processed for embedding at SCH using a Sakura Tissue Tek TEC 5 
Tissue Embedding Console. The SCH standard fixation program was used, which takes 
12 -16 hr to complete. To dehydrate the tissue, the processor immerses the cassette 
into multiple baths of progressively concentrated ethanol with final rinses of 100% 
ethanol. The clearing stage then replaces the ethanol with a number of 100% xylene 
rinses. Upon completion, the dehydrated tissues are miscible with paraffin. Processed 
tissue is taken out of the cassette by a technician and set in a metal mould containing a 
small amount of liquid paraffin. After the sample is levelled in the mould, additional 
paraffin is added on top to create the final paraffin block 166,167. 
After some experimentation, optimal fixation for cytospin and EZ-slides was 
determined to be 30 min in 10% buffered formalin. After formalin fixation, cell culture 
slides were placed into sterile PBS and immediately brought to the SCH IHC Laboratory 
for staining.   
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2.4 TMA assembly 
 
TMAs provide a way to compile multiple tissue samples that were processed 
independently of each other (at one or more laboratories) into one paraffin block. This 
composite block can be sectioned onto slides to simultaneously evaluate these samples 
together 168. Microarrays are constructed by acquiring a small punch core sample from 
areas of interest in FFPE samples. Cores are incorporated into a recipient paraffin block 
and heated to permanently bond the block together. Construction of duplicate blocks, or 
blocks with multiple sections of the same tumor in it, allows for immediate comparison, 
and large savings, in research that was not previously possible 168–170. Core samples 
are commonly sampled as 0.6 mm, 1 mm or 2 mm cores, depending on the area of 
interest, the type of lesions being evaluated, and the type of analysis performed on the 
block. TMAs are optimally suited for IHC IA analysis because the selection of the areas 
for analysis is included as part of the sample core collection 171–173.  
2.4.1 Sample selection and core collection 
 
The first step in TMA design is the selection of samples for inclusion. In this study, 
microarrays created from FFPE cell lines were assembled by myself and, in the case of 
tissue controls, by the histology laboratories of SCH (Saskatoon, SK), Vancouver 
General Hospital (VGH) (Vancouver, BC) and Jewish General Hospital (JGH) (Montreal, 
QC). Searches of databases with records relevant to quality assurance operations were 
performed to ensure that FFPE breast tumor blocks with varying levels of expression of 
ER, PR and HER2 were selected. Data search for QA purposes is exempt from  
Research Ethical Board review.  
Areas of interest in the FFPE blocks were identified from ER, PR and HER2 IHC-
stained slide sections of each block. Punch cores (1 mm and 2 mm) were taken from 
the selected areas using the donor punch of the Beecher TMA instrument. Two to three 
cores were taken from each block, depending on the tumor size. Cores were stored in 
labeled 0.5 mL microcentrifuge tubes in a cool dark place until assembled into a finished 
array at a later time. A sample bank of cores was created in this manner with the 
identity of samples kept confidential. Records linking patient data to de-identified 
samples were kept in a secure location separate from TMA information. 
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2.4.2 Block assembly 
 
 A recipient block was created for each array by standard methods 168,173. Paraffin 
cores were removed from a blank paraffin block using the recipient punches of the 
Beecher TMA instrument. A linear distribution of 1 mm was left between each hole. The 
1 mm punch was damaged partway through this study and the 2 mm punch was 
adopted to complete the study. Cores were placed into the recipient block using the flat 
end of a stainless steel spatula, which was carefully cleaned between samples. The 
identification and location of each core was recorded. When completed, the block was 
placed paraffin-side down onto a clean glass microscope slide and heated to 40°C for 
20 min. Following this, the block was firmly and evenly pressed down onto the glass 
slide. The block and slide were immediately placed onto a block of ice for 30 min to cool 
the paraffin block evenly. Once cooled, the slide was gently removed from the 
completed array 173. 
2.4.2.1 Microarray blocks used in this project 
 
A number of array blocks were assembled for this project. They are described in 
detail below. 
 
cIQc Run 13 TMA and CLMA: cIQc Run 13 TMA was a neoplastic and benign human 
TMA assembled at a cIQc Program Laboratory (University of British Columbia, 
Vancouver, BC). This block, referred to in this study as “Run 13 TMA” contained 56 
tissue cores: six rows of nine cores each, with two control alignment cores of FFPE 
human liver tissue added to the top left of the block. Nine FFPE cell line samples for 
Run 13 were placed into a separate CLMA block. This block was used in a cIQc EQA 
run for ER, PR and HER2. 
 
Special Run TMA/CLMA: An array block, hereafter referred to as “Special TMA” was 
assembled in our laboratory. This array contained 47 cores. There were five rows of 
nine cores, with two alignment cores of FFPE benign control liver tissue on the top left 
of the block. The first two rows were 2 mm cores of all nine cell lines. The remaining 27 
tissue cores were 1 mm tissue cores of FFPE breast cancer blocks selected and 
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donated to cIQc by JGH. This block was used in a cIQc EQA IHC run for ER, PR and 
HER2. 
 
Final CLMA: For the CLMA used for PT in this project, a search of an internal SHR 
database of ER-stained, PR-stained and HER2-stained breast cases from 2005-2009 
was performed. A total of 110 cases were selected with varying levels of expression of 
ER, PR and HER2, with tumor sections large enough to get two or three 2 mm cores 
from each block. Needle biopsies, cases originating from external hospitals, rare cases 
and tumors smaller than 1 mm were excluded. From this initial group, 22 FFPE case 
blocks were selected. This array, referred to hereafter as “Final CLMA”, contained 38 2 
mm cores. The Final CLMA was a six by six grid of cores, with two alignment cores on 
the top left of the block. Two cores of each of the nine cell lines (18 total) and 22 cores 
of tissue were included in this block. This was the final array created for this study. 
 
JGH CLMA: JGH assembled a HER2 IHC control array containing 16 FFPE breast 
tumor samples. This array also included two FFPE cell lines created for this project (AU-
565 and MDA-MB-231). Four tissues cores were selected from each HER2 Score (0 to 
3+). Cell line AU-565 was included because it has strong HER2 IHC staining (HER2 
Score = 3+). Cell line MDA-MB-231 was included because it is negative for HER2 IHC 
staining. Sequential slides from this block were used as HER2 IHC controls at JGH. The 
HER2 control slides were sent to me for IA once JGH analysis with them was 
completed. 
2.5 IHC 
 
This section gives a description of the IHC-staining process, from the sectioning of 
the block onto the slides through the pre-analytical, analytical and post analytical stages 
to the finished slide. 
2.5.1 Sectioning 
 
FFPE block sections were cut at SCH on a Leica RM2235 microtome.  Four-micron 
thick sections were floated onto positively charged microscope slides using a distilled 
water-filled, warmed tissue bath with no additives. Excess water was then blotted from 
  33 
the slide, allowing it to air dry. For optimal staining, slides that would be stained within 2-
4 days of cutting were stored at 4°C, while slides stored for a longer time were kept at -
80°C 174. Prior to IHC, chilled slides were thawed and completely air-dried (if required) 
for 2-3 hr before de-paraffinization. 
2.5.2 De-paraffinizing and rehydration 
 
It is important to remove all the paraffin from the sample for reproducible and 
complete IHC staining. Initial baking of the slides at 60 °C for a minimum of 1 hr 
(maximum overnight) begins this process. Once the deparaffinizing and rehydration 
process begins, the slides cannot be allowed to dry out at any time or the resulting IHC 
stains may have high background and non-specific, uneven staining 36. 
To remove paraffin, the baked, cooled slides were placed into a TissueTek II slide 
tray. The slide tray was placed in a series of solutions, with a vigorous agitation at the 
start of each step. Four 5 min xylene washes began the process to remove remaining 
paraffin from the sections. This was immediately followed by 3 X 10 sec 100% ethanol 
washes, 2 X 10 sec 95% ethanol washes and a 1 min 70% ethanol wash. Following 
this, the slides were placed thoroughly rinsed with numerous distilled water rinses to 
remove all ethanol. Rehydrated slides were placed in distilled water or PBS, and 
processed with HIER 36,87. 
2.5.3 HIER 
 
For FFPE tissues, it is usually necessary to pre-treat the tissues with HIER in order 
to de-mask epitopes for optimal staining (Section 1.2). HIER is optimized for each tissue 
type and antibody 175. For ER, PR and HER2 IHC, SCH uses the following optimized 
HIER method. De-paraffinized, rehydrated slides were placed into a TissueTek II slide 
tray containing freshly prepared 1 mM EDTA (pH 9.0). Any empty places on rack were 
filled with blank glass slides to ensure consistent heating. To prevent explosion during 
heating, the lid was loosely placed on the full buffer chamber containing the slides.  
The slides were heated in an 1100 W microwave for 13 min at 60% power. After 
this, the slides were left in the hot buffer for another 20 min before rinsing briefly with 
room temperature distilled water. Once the slides cooled to room temperature, they 
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were thoroughly rinsed with running distilled water for 2 min to remove all EDTA 36,47,52. 
Slides were kept in distilled water until they were loaded onto the IHC autostainer. 
For cytospin and cell culture slides, the fixation process is less harsh, requiring a 
less harsh HIER procedure. Standard HIER at SCH for cytospin slides is to place them 
into pre-boiled EDTA HIER buffer for 15 min before cooling and rinsing with distilled 
water prior to IHC. Alternatively, FFPE cell line slides (cut from blocks containing cell 
pellet material processed the same as human tissue) received the same HIER as 
regular biopsy samples.  
2.5.4 Immunostaining  
 
All IHC slides for this project were stained at SCH on a Dako Autostain Plus IHC 
instrument with Dako Envision Plus reagent kits. Specific Envision Plus kits were paired 
with their appropriate primary mouse, goat or rabbit antibodies. The autostainer has a 
hydration chamber to maintain humidity and prevent the drying out of slides during 
staining. Manual staining is done with the aid of a small hydration chamber for 
incubations that prevents dehydration.  A summary of the IHC methodology and 
procedure follows. 
De-paraffinized HIER-prepared slides were marked with a Dako hydrophobic 
marker on either end of the slide to help contain the stain solutions on the slide surface. 
Slides were then loaded onto the autostainer and Dako IHC buffer was placed on top of 
the slide until the procedure began. A standard IHC protocol was entered into the Dako 
Autostainer software program. This protocol begins with a 5 min block step to remove 
endogenous peroxides, followed by a buffer rinse. The next step is a 30 min primary 
antibody incubation followed by two buffer rinses. The next step is a 30 min secondary 
antibody incubation step followed by two more buffer rinses. Final 10 min DAB 
chromagen incubation is followed by a distilled water rinse. The Envision Plus kits 
contain the peroxidase block solution, polymer HRP-labeled secondary antibody and a 
DAB chromagen solution. A total of 300 µL of all solutions were used for each slide 
stained. 
It is SCH policy to have sections of control blocks mounted onto all sample slides 
before staining. Controls are specific for the antibody used. The monoclonal primary 
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antibodies used in SCH IHC-staining of patient samples have been validated for use. 
Optimal dilutions are re-evaluated with every batch received. During this study, rabbit 
anti-human ER (α-subunit) antibody (Thermo Scientific, Clone SP1) was diluted to 1/50 
before use. Mouse anti-human PR (A-isoform) antibody (Novocastra, Clone 16) was 
diluted to 1/100 before use. Rabbit anti-human HER2 antibody (Thermo Scientific, 
Clone SP3) was diluted to 1/250 before use. Antibodies were diluted with Dako antibody 
dilution buffer.  
2.5.5 Dehydration, counterstaining and coverslipping 
 
After IHC, the slides were placed in distilled water to be counterstained and 
coverslipped. DAB staining was enhanced with a 5 min incubation in 2% (w/v) copper 
sulphate solution (made fresh weekly). Slides were rinsed under running room-
temperature tap water for 5 min. Following this, unstained tissue was counter-stained 
with 15 dips into light Hematoxyllin 1. Slides were thoroughly rinsed with room-
temperature tap water. To optimize the blue counterstain, the slides were then placed 
into freshly prepared alkaline water (200 mL distilled water + 0.5 mL ammonium 
hydroxide) for 30 sec and then rinsed well with running room-temperature tap water. 
Slides were dehydrated in a fume hood using a TissueTek II tissue stain rack. 
Slides were placed in a series of ethanol washes (~10 sec per rinse, 10 times vigorous 
dips up and down). Three washes of 95% ethanol were followed by three washes of 
100% ethanol to remove all water. A final four washes of xylene removed all traces of 
ethanol. Slides were stored briefly in xylene until they could be covered with 20 mm X 
40 mm coverslips and Permount mounting medium. 
2.5.6 Interpretation of results  
 
Current ASCO/CAP guidelines used for the scoring of ER, PR and HER2 IHC 
results were discussed in the Introduction Section and in more detail immediately below 
7,20. The guidelines basically apply to visual inspection by an experienced pathologist 
using a light microscope, but also include guidelines for scoring by IA. HScore value can 
be derived from visual inspection and counting of cells, but is much faster to do derive 
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HScore using IA. An example of nuclear (ER, PR) and membranous (HER2) IHC 
staining of FFPE tissue and cell lines can be seen in Figure 1. 
It is important to note that the expert assessment by cIQc Program differs from the 
above guidelines and is limited to establishing whether the PT samples are positive or 
negative for a specific marker. These expert-assessor scoring results are used to 
calculate a participating laboratory's level of IHC-stain sensitivity, specificity and κ in 
relation to a designated reference value. In this project, the pass/fail rate of participating 
laboratory the performance was compared to their success rate, which was observed 
using HScores calculated from IA algorithm results. HScores were used for LSRSR 
calculations (Section 2.6.3.4) and the creation of QC control charts (Section 2.6.3.2). 
Because the methods of scoring are different, the cut off points regarding the pass/fail 
rates are also different for each method. The cIQc Program expert assessment pass/fail 
cut off was at 90% sensitivity, with specificity and κ cut off set at ≥ 0.80 (near perfect 
agreement). The IA/LSRSR pass/fail cut off was when participating laboratory LSRSRs 
fell outside of the reference LSRSR range for multiple sample measurements.  
2.5.6.1 ER, PR and HER2 IHC scoring 
 
Estrogen and progesterone receptors are located in cell nuclei. Irrespective of the 
method used, IHC staining is deemed to be “positive” for ER and PR if greater than 1% 
of the total nuclei are at least weakly positive. Both intensity of staining and the 
percentage of positive cells are assessed. For ER and PR, positivity is defined as a 
change in color of the nucleus of the tumor cells from blue (negative) to gray (weakly 
positive) or brown (moderately and strongly positive).  
HER2 is a membranous receptor. As discussed in section 1.1.3, a HER2 score of 3 
indicates a clinically positive sample. HER2 score of 2 is defined as equivocal and it is 
obligatory to study these tumors by FISH, to confirm if the sample is considered a true 
positive or not 9,10. A HER2 score of 1+ and 0 are applied to clinical practice as 
negative, and the patients with such tumors do not qualify to receive targeted therapy. 
Although such scoring is used in clinical practice, the focus of this work is not to stratify 
patients for therapy, but rather to address technical aspects of variation in calibration of 
the methods. Therefore, the above semi-quantitative scoring was not used because it is 
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Figure 1: Nuclear and Membranous IHC-Staining of FFPE Tissue and Cell Line 
Cores. Brown color is positive staining for protein of interest. Blue staining is 
counterstaining of negative tissues with hematoxyllin. A, tissue, nuclear IHC stain; B, 
cells, nuclear IHC stain; C, tissue, membranous IHC stain; D, cells, membranous IHC 
stain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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not suitable for calibration due to a very narrow value range.  For this reason, HScores 
of HER2 IHC results were used in this research. Monitoring of calibration is essential to 
decrease variation in the system and provide reproducible results, which can then be 
interpreted on any clinically acceptable scale for patient treatment.  
2.5.6.2 Linearity of IHC staining 
   
IHC staining is a cumulative process, with primary antibodies binding to epitopes of 
interest, followed by secondary, HRP-labeled antibody binding to the primary antibody. 
The Dako Envision Plus reagent kit used in this project uses a secondary antibody that 
is bound to a polymer, which is in turn bound to a large number of HRP molecules. This 
polymer-HRP-bound secondary antibody is designed for intense staining efficiency. The 
Lambert–Beer law usually used in determining the linear useful linear range of a 
chromagen can only be applied to pure absorbing compounds. The DAB chromagen 
used in IHC, exhibits a scattering behavior, and is spectrally identical to natural 
pigments like melanin 32. Luckily, a reasonable dynamic range of measurement can 
achieved using DAB together with IA algorithms that are optimized for DAB. Other red-
based stains that show better linear ranges for IA measurement are not commonly used 
in clinical IHC 176.  
Currently used IHC detection systems are designed to amplify the observed staining 
signals. This amplification results in a logarithmic type of association with the 
concentration of target epitopes. However, lower levels of protein/epitope and higher 
antibody dilutions have been shown to result in a more linear range of staining, which 
allows for quantitation of the epitope in the tissue. In contrast, more highly expressing 
tissues will show less variation in the intensity of the signal because the system 
oversaturates at higher expression levels. Therefore, positive controls with weak 
expression of epitopes are recommended for both manual and IA systems 10,21,22,177.  
2.6 IA 
 
IA can reduce human error in IHC interpretation 32,139. This project examined the 
application of IA in IHC for use in EQA and PT. IA provides a non-subjective 
reference/scoring method for evaluating the staining performance of one or more 
laboratories 161. IA was also applied to daily QC for the interpretation of in-laboratory, 
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on-slide controls to evaluate run-to-run performance. A combination of digital IA 
evaluation of IHC of ER, PR and HER2 with cells lines as positive controls and 
HScore/LSRSR evaluations were applied. 
2.6.1 Aperio scanner 
 
The Aperio Scanscope CS system used in this project is a powerful three CCD 
quantitative camera that captures 20X digital images from five slides at a time, using a 
high quality microscope. Once the digital image is saved to a server, the Aperio 
Spectrum (version 11) software works in consort with Aperio Imagescope viewing 
software (version 10). Through Spectrum, appropriate algorithms were applied to digital 
images to identify cellular structures and measure DAB stain intensity. Aperio TMALab 
software (version 10) was used for scoring and analysis of TMA slides using the same 
algorithms. Numerical results were exported in Excel 2007 format for further analysis.  
2.6.2 Algorithms for assessment 
 
The algorithms used in this project have been optimized by Dr. Emina Torlakovic for 
use in the cIQc EQA Program. This optimization ensured that the algorithm results 
correlated with clinically used cut off points. IA algorithms are calibrated using 
measurements of the RGB values of the positive DAB (brown) and negative 
hematoxyllin (blue) stains used in the SCH IHC Laboratory. This calibration reduces 
small variations in the measured colour spectra that can have quite dramatic effects on 
the algorithm-calculated values in higher staining samples 32. 
These calibrated RGB values were used for all slides in this project. Stain intensity 
value ranges for 0 (negative), 1+, 2+ and 3+ (highest intensity) were defined by Aperio 
in the their algorithms. These algorithms can identify individual cells and cell nuclei, but 
cannot differentiate tumor from normal tissue. Specific areas of interest on a slide must 
be pre-selected for IA to ensure appropriate analysis. Algorithms can be applied to a 
whole image, a selected annotation of an image or individual cores of a TMA.  
Two Aperio algorithms (specifically modified and calibrated as described above) 
were used for this project. “ET Nuclear IHC new colours” measures nuclear DAB 
staining intensity for ER and PR IHC. “ET IHC Membrane for RUN5” measures 
completeness of membrane staining and DAB membranous stain intensity for HER2 
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IHC. These algorithms use mathematical formulae to identify nuclei and membranous 
structures. The RGB stain intensity of each region is measured, and the cells are 
classified into the appropriate stain intensity. The total number of measured cells, nuclei 
and complete membranes are determined. The percentage of total cells of each 
intensity (0 to 3+) is then calculated. A virtual annotation image overlay can be created 
during analysis to allow the user to visually determine that IA has been applied 
appropriately. This overlay uses a different colour for each intensity range: Red for 3+, 
orange for 2+, yellow for 1+ and blue for 0. Detailed algorithm settings are listed in 
Supplemental Table 1. 
TMALab software allows for a TMA map to be created for IA. Each slide can be 
manually mapped to a template. Once all slides and cores are manually identified, each 
core can be analyzed individually with any algorithm. TMALab was used in this project 
for IA of individual cores in all TMAs and CLMAs. 
In IA, damaged or folded TMA cores can be erroneously scored. Overlapping and 
damaged tissues will be interpreted by IA colour measuring algorithms to be more 
intensely stained than they actually are. IA algorithms may also incorrectly record a 
missing TMA core as a negatively staining core. Visual inspection of slides and IA 
results are required to identify and exclude any improperly analyzed cores.  
2.6.3 Statistical analysis 
 
IA HScore results were statistically compared as indicated in the results (t-tests, F-
tests, κ and Chi-squared analysis of variance). IHC-stain results and laboratory results 
in the cIQc EQA Program were graphically compared through QC charts, histogram 
plots and boxplots of HScores and LSRSRs. SPSS 19 and Excel (2007 and 2011) were 
used for all statistical analyses. 
2.6.3.1 HScore  
 
Completed algorithm scoring data is exported as an Excel compatible spreadsheet. 
IA data from each slide was exported as a separate file. Individual slide and core data 
was later manually copied and pasted together into summary worksheets for analysis.  
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HScores were calculated using the following formula 81: 
 
HScore = 3 x (percent 3+ cells) + 2 x (percent 2+ cells) + 1 x (percent 1+ cells) 
 
IA HScores were used to derive LSRSR values as described in Section 2.6.3.4  
2.6.3.2 Levey Jennings control charts 
 
Levey Jennings control charts were created with a template created in Excel 2007. 
HScores calculated from the IA results of individual controls, analyzed over time, were 
pasted into this Excel template. A Levey Jennings control chart112 places each daily 
measured control progressively on the X-axis of the graph. The HScore of each control 
sample is plotted on the Y-axis. Two and three SD from the mean of the HScore data 
set are calculated and plotted on these graphs, allowing for the visualization of any 
samples that fell outside of the acceptable performance range 112,113,115,133. Some study 
results are expressed as Levey Jennings QC charts. 
2.6.3.3 cIQc PT performance - the use of Garratograms 
 
In the cIQc EQA Program, a group of expert pathologists and technologists evaluate 
ER, PR and HER2 IHC-stained slides submitted by participating laboratories. Scoring 
results are expressed as garratograms (to credit the contribution of John Garratt from 
Vancouver, BC who first used heat maps in EQA to illustrate concordance of results 
between participating laboratories). Garratograms allow for visual comparison of stain 
results of a reference laboratory or method to that of a participating laboratory. Different 
colors are used to designate results. In a garratogram, samples showing positive 
staining (>1% nuclear staining) are denoted with red squares, negatively staining 
samples are denoted with white squares and unacceptable or missing samples are 
denoted as yellow cores. When the results of all cores for all participating laboratories 
are lined up beside those for reference laboratories, any cores improperly stained are 
easily identified. Laboratories are considered to have acceptable staining method if they 
have ≥90% agreement or the same level of sensitivity and specificity with reference 
laboratory results. κ (a statistical measure of inter-rater agreement) is also calculated to 
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compare participant IHC stain scoring to cIQc stain scoring. A κ ≥ 0.8 (nearly perfect 
agreement) is considered acceptable performance. 
2.6.3.4 LSRSR calculation 
 
This project applied LSRSR calculations as an indirect scoring method and a 
calibration tool to compare and measure performance of laboratories in the cIQc EQA 
Program through IA. LSRSR is calculated from HScore values calculated from IA data. 
To calculate LSRSR, the HScore of each participating laboratory is divided by the 
HScore of the reference or reference laboratory, which is used as a “gold standard”. 
What is used as a reference result may vary; either a single reference laboratory’s 
results or, alternatively, an average HScore of multiple reference laboratories may be 
used. As no definite true “gold standard” exists for calibration of IHC methods and 
results, a number of reference core samples and laboratories are used to increase the 
accuracy of the selected reference results in EQA. 
 In this study, the HScore of a participating EQA laboratory is divided by the 
average reference HScore of six selected reference laboratories to create a ratio. This 
ratio is the LSRSR for that laboratory for any specific tissue or cell line sample (tissue 
core or cell line core or any other sample selected for this purpose). LSRSR reflects the 
degree of agreement between the participant and the average reference result and, 
ideally, it is 1.00. LSRSR is usually calculated for the reference laboratories for a 
number of representative cores (four to six) to give the acceptable LSRSR range for 
each core (although any number of samples may be included by the EQA program for 
this purpose). The minimum and maximum LSRSR values from the six selected 
reference laboratories was the acceptable LSRSR reference range for participating 
laboratories for any sample in an EQA PT run. Although many tissue samples are 
included on the test slides, only a few selected tissue (or cell line) samples are used for 
LSRSR calculation. Sample selection is based on the reference laboratory HScore for 
that sample, which should optimally be in the informative, more sensitive, HScore range 
(50-100 whenever possible). HScores of participating laboratories are divided by the 
average reference HScore value for each of the selected informative tissue or cell line 
samples. LSRSR scores that fall within the reference LSRSR ranges indicate that 
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participating laboratory results are in the range of reference laboratories results and that 
the participant is performing in an acceptable manner for the particular EQA 
assessment. 
The creation of an acceptable LSRSR reference range is best depicted graphically. 
The average HScore was calculated from the IHC HScores of the six preselected 
reference laboratories for each of the selected informative samples (either tissue cores 
or cell line cores). This average HScore was then used as the denominator to calculate 
an LSRSR for each reference laboratory for each informative sample. Reference 
laboratory LSRSRs are then plotted on the y-axis, with each informative sample as a 
point on the x-axis. When all LSRSR are plotted, the minimum and maximum reference 
LSRSR for all the informative samples are easily identified and any extreme outliers can 
be identified and excluded. The minimum and maximum LSRSR values from this graph 
become the acceptable reference LSRSR range for that specific IHC stain PT run. 
Extreme LSRSR values were identified and selected as outliers using a form of delete-1 
jackknife resampling 178,179. By this method, any graphed values that appeared to be 
outliers were identified. These suspect values were removed, one at a time, from the 
graphed data group. The acceptable LSRSR range was re-evaluated once this value 
was removed. If the suspected LSRSR was outside the revised acceptable LSFSR 
range, then the suspected value was discarded. This acceptable reference LSRSR 
range was then used in PT evaluation of all participating laboratories 161.  
2.6.3.5 Boxplots and histograms 
 
The closer a laboratory LSRSR value is to 1, the closer the IHC staining of that 
laboratory is to that of a reference laboratory or laboratories. Graphically plotting the 
LSRSR or HScore of a laboratory as a histogram and boxplot will visually represent a 
laboratory’s EQA IHC performance in comparison to the entire test group. Poor 
performance is easily visually identified using these plots, making them a useful method 
of presenting EQA results to participating laboratories. 
2.7 RT-qPCR  
 
To more effectively use cell lines as IHC controls, it is important to observe the 
consistency of expression of ER, PR and HER2 in FFPE cell lines after processing 
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through FFPE and HIER for IHC staining. Formalin fixation and paraffin embedding may 
damage proteins of interest 160. Decay kinetics of transcripts and proteins from the IHC 
procedure are not yet known for FFPE samples.  
The laboratory at the University of British Columbia (Vancouver, BC), which 
prepares the majority of cIQc Program FFPE samples for EQA, generously arranged for 
RT-qPCR analysis of ER, PR and HER2 gene expression in the nine cell line blocks 
used in this project. Such transcriptional analysis of ER, PR and HER2 allows 
comparison with the protein levels observed via IA IHC. These RT-qPCR results should 
provide insight into the possible degradation of ER, PR and HER2 in the processing of 
my FFPE cell line samples during IHC staining. This knowledge should be helpful in the 
practical application of these cell line samples as IHC control samples 155,157,158,160. 
The RT-qPCR analyses were performed at the Bernard Laboratory at the University 
of Utah using a previously optimized method 157. RT-qPCR analysis to measure ER, PR 
and HER2 gene expression was carried out with mRNA extracted from the nine FFPE 
cell lines in this project. This was done using a Qiagen Total RNA extraction kit. cDNA 
was prepared with SuperScript III (Invitrogen) and a Qiagen DNA clean up kit. Two 
replicates of each sample were on a Roche LightCycler480 RT-qPCR instrument, using 
Roche Master Mix double-stranded DNA-specific dye 157,158. 
Results were analyzed with Profiler software. Results are expressed by a relative 
quantification method 157, using an external efficiency curve in which the calibrator gene 
is valued at 10 ng. To correct for differences in sample quality and cDNA input, the 
normalized sample ER, PR and HER2 copy numbers were then adjusted relative to the 
results for five housekeeping genes. Adjusted sample results were then averaged to 
obtain the final relative RT-qPCR gene expressions 157,158.  
A slide of a CLMA containing the cell lines was also cut and IHC stained for ER, PR 
and HER2 by cIQc reference laboratories. The IA-calculated HScores allow for 
comparison of IHC-measured ER, PR and HER2 expression with measured ER, PR 
and HER2 mRNA levels. 
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2.8 Collaboration 
2.8.1 cIQc involvement 
 
The EQA/PT component of this project was possible due to collaboration with the 
cIQc Program. As previously described, the cIQc Program created and sectioned the 
slides, and was responsible for the delivery of slides to participating laboratories. cIQc 
pathologists and technologists evaluated Run 13 PT slides and shared their 
garratogram scoring results. All cIQc Program participating laboratories were included in 
the final data evaluations. The cIQc Program selected statistically relevant numbers of 
reference material for EQA TMA assembly. The reference laboratories used for LSRSR 
calculations were selected by the cIQc program based on consistent previous EQA 
performance, from the initiation of the EQA program up until the present. 
2.8.2 Laboratories involved 
 
This project was completed in collaboration with a number of Canadian clinical IHC 
laboratories. The SCH performed all the paraffin embedding of my cell pellet blocks as 
well as the sectioning and IHC staining of these blocks onto slides. SCH was one of the 
cIQc founding IHC laboratories and continues to participate in the cIQc Program, where 
it has been graded as one of the reference laboratories. SCH performed the IHC-
staining of ER, PR and HER2 slides from the cIQc CLMAs and TMAs of the cIQc 
Program. SCH also included Final CLMA slides into their daily IHC runs for my 
interpretation with IA and Levey Jennings QC charts. The FFPE blocks used to create 
my Final TMA were selected from a SHR breast cancer patient database. The tissue-
based control slides for ER, PR and HER2 were selected from the SHR 2009 slide 
archives for analysis by IA with QC charts. 
Jewish General Hospital (JGH) from Montreal, Quebec, another cIQc reference 
laboratory, contributed a number of FFPE breast cancer tissue samples used in the 
Special CLMA in this project. JGH also generously agreed to include two of my cell line 
blocks into one of their FFPE on-slide HER2 IHC control blocks. Once patient diagnosis 
was complete, JGH submitted this set of control slides to me for IA and QC chart 
analysis. JGH also generously donated sets of tissue-control slides for IA QC chart 
analysis of current in-laboratory tissue controls.  
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Vancouver General Hospital (VGH), Vancouver, British Columbia, is currently a 
core laboratory for the cIQc Program. Clinical and academic research laboratories, 
under the advisory of Dr. Blake Gilks and John Garratt, create and section the TMAs 
used in the cIQc EQA Program. The University of British Columba research laboratory 
arranged for RT-qPCR analysis of the nine cell line FFPE blocks created for this project 
at the Bernard laboratory at the Huntsman Cancer Institute of the University of Utah, in 
the United States.  
Two laboratories that regularly participate in the cIQc Program, from Edmonton, 
Alberta and Toronto, Ontario have made available several sets of ER-, PR- and HER2-
stained on-slide IHC human tissue controls to this project. These sets of tissue-control 
slides were used for IA and QC chart analysis in this project.  
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3.0 STUDY RESULTS 
 
The three hypotheses of this study were addressed in a number of PT and QC 
experiments. The detailed data relevant to each hypotheses are presented in this 
section.  
3.1 Introductory work 
3.1.1 Cell line block creation, slide scanning and IA evaluation 
 
Slides prepared from FFPE blocks of nine human breast cell lines (AU-565, BT-474, 
HBL-100, HS-578T, MDA-MB-231, MDA-MB-435, MCF-7, T47D, SKBR-3) were 
processed in the same manner as human tissue samples at the SCH Laboratory. FFPE 
Cell line IHC-staining for ER, PR and HER2 were observed to be comparable to that of 
FFPE tissue samples. Figure 2 presents sample images of such nuclear and 
membranous IHC staining of FFPE tissue and cell lines. IHC staining of cell lines was 
confirmed by the identical IHC staining of non-paraffin embedded EZ-Slide and cytospin 
cell line preparations. All FFPE cell line slides were digitally scanned and analyzed with 
IA. Analysis overlay images confirmed that cell lines were accurately recognized and 
scored by the software (Figure 2). The resulting data was used to calculate HScores for 
project analysis. 
3.1.1.1 IA reproducibility of IA and reproducibility of cell block samples (biological 
homogeneity) 
 
A single slide section from the first created cell line block (T47D) was stained for PR 
at SCH laboratory and scanned 10 separate times. Each separate scan image was 
analyzed with IA between one and five separate times. The resulting calculated mean 
HScore for all scans and IA scoring was 282.1 ± 0.3 (Table 1). This demonstrated 
reproducibility of the Aperio IA system for scoring FFPE IHC-stained samples. 
Next, the biological homogeneity of cell lines was examined throughout an entire 
FFPE cell line block. A single T47D cell line block was completely sectioned onto slides. 
Random sections from throughout the depth of the block were stained for PR at SCH 
Laboratory.   PR  IHC  was  selected  because it tends to be less reproducible in human   
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Figure 2: IA Scoring and Calculation of HScore. Stain scores can be used to 
calculate an HScore which reflects the overall total staining of the tissue section. 
HScore= (3*(3+)) + (2*(2+)) + (1*(1+)). A, nuclear IHC staining (ER and PR); B, nuclear 
staining with IA analysis; C, membranous IHC staining (HER2); D, membranous 
staining with IA analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0=blue, 1+= yellow, 2+= orange, 3+= red. 
  
A B 
D C 
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Table 1. Reproducibility of IA for IHC PR Staining.a 
 
Scan 
Algorithm 
Rep 
(3+)  % 
Nuclei 
(2+) % 
Nuclei 
(1+) % 
Nuclei 
(0+) % 
Nuclei HScoreb 
1 1 91.0 3.5 1.7 3.8 281.7 
1 2 91.0 3.5 1.7 3.8 281.7 
1 3 91.0 3.5 1.7 3.8 281.7 
1 4 91.0 3.5 1.7 3.8 281.7 
1 5 91.0 3.5 1.7 3.8 281.7 
2 1 91.4 3.3 1.6 3.7 282.4 
2 2 91.4 3.3 1.6 3.7 282.4 
2 3 91.4 3.3 1.6 3.7 282.4 
2 4 91.4 3.3 1.6 3.7 282.4 
2 5 91.4 3.3 1.6 3.7 282.4 
3 1 91.3 3.3 1.6 3.7 282.3 
3 2 91.3 3.3 1.6 3.7 282.3 
3 3 91.3 3.3 1.6 3.7 282.3 
3 4 91.3 3.3 1.6 3.7 282.3 
3 5 91.3 3.3 1.6 3.7 282.3 
4 1 91.4 3.3 1.6 3.7 282.5 
4 2 91.4 3.3 1.6 3.7 282.5 
4 3 91.4 3.3 1.6 3.7 282.5 
4 4 91.4 3.3 1.6 3.7 282.5 
4 5 91.4 3.3 1.6 3.7 282.5 
5 1 91.1 3.4 1.7 3.8 281.8 
5 2 91.1 3.4 1.7 3.8 281.8 
5 3 91.1 3.4 1.7 3.8 281.8 
5 4 91.1 3.4 1.7 3.8 281.8 
5 5 91.1 3.4 1.7 3.8 281.8 
6 1 91.4 3.3 1.6 3.8 282.3 
7 1 91.4 3.3 1.6 3.7 282.5 
8 1 91.2 3.4 1.7 3.7 282.1 
9 1 91.4 3.3 1.6 3.7 282.4 
10 1 91.4 3.4 1.6 3.6 282.6 
     Mean 282.1 
     SD 0.3 
 
aMultiple scans and analyses of one PR-stained T47D cell block slide at different times. 
 
bHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
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tissue samples. IA of 20 of these different levels resulted in a mean HScore of 284.7 ± 
2.4. This demonstrated biological homogeneity and consistency of staining for cell lines 
throughout the depth of the FFPE block (Table 2). 
Cell lines were divided up into Low (HScore <50), Medium (HScore, 50-150) and 
High (HScore >150) groups. Although there was a variation in stain intensity of cell line 
blocks from run to run, cell-line HScores were reproducible and were not significantly 
different throughout the numerous IHC-stain runs. Stain results for the nine cell line 
blocks throughout all the different the study trials can be seen in Table 3. Slides from 
the initial FFPE cell line blocks and the Final CLMA block (discussed later) were stained 
at the SCH Laboratory. EQA IHC results for cell lines are an average of HScores from 
many laboratories. 
3.1.1.2 Limitations of IA  
 
When scanning tissue samples, a difficulty with IA was observed. IA algorithms 
could not be modified to reliably differentiate tumor tissue from normal tissue. 
Consequently, areas for analysis must be specifically selected or screened for IA prior 
to analysis to ensure that non-valid areas are not measured and erroneously used for 
evaluation. It was observed that damaged or folded TMA cores are erroneously scored 
by IA to have falsely higher IA intensity score values. Overlapping and damaged tissues 
have a darker colour and are therefore interpreted by IA colour measuring algorithms to 
be more intensely stained than they actually are. In Figure 3, circles denote areas of 
cores where IA-measured stain intensities were incorrectly measured. IA algorithms 
may also, rarely, incorrectly record a missing TMA core as a negatively staining sample. 
Consequently, all slides used in analysis in this project were individually inspected to 
remove IA error due to lost, folded or damaged samples. 
3.1.2 IA in PT: cIQc Run 13 and cIQc Special Run 
 
For IA of PT samples, sectioned TMA slides were stained and returned from 
participating cIQc Program laboratories. For Run 13, slides stained for ER, PR and 
HER2 were received from 46, 45 and 37 laboratories, respectively.  Of these slides, 46, 
41 and 34 laboratories were of sufficient quality to be analyzed by IA for ER, PR and 
HER2, respectively.   Run 13 TMA cores were analyzed and scored as either positive or 
  51 
Table 2. Cell-line Block IHC PR Staining Consistency.a 
 
Slide 
(3+) % 
Nuclei 
(2+) % 
Nuclei 
(1+) % 
Nuclei 
(0+) % 
Nuclei HScoreb 
1 92.0 3.0 1.7 3.4 283.6 
2 93.3 2.5 1.3 3.0 286.0 
3 89.2 3.9 2.7 4.2 278.2 
4 93.6 2.1 1.3 3.0 286.2 
5 93.9 1.7 1.1 3.3 286.1 
6 93.7 2.1 1.2 3.0 286.5 
7 93.5 2.4 1.3 2.9 286.4 
8 92.8 2.6 1.4 3.2 285.1 
9 94.5 1.8 1.0 2.7 288.1 
10 92.5 2.9 1.5 3.1 284.9 
11 92.8 2.9 1.3 3.0 285.6 
12 93.8 2.3 1.1 2.8 287.1 
13 93.7 1.9 1.3 3.0 286.4 
14 93.3 2.7 1.3 2.7 286.7 
15 91.5 3.1 1.8 3.6 282.5 
16 91.5 3.3 1.9 3.3 283.0 
17 92.2 3.1 1.8 2.9 284.7 
18 92.1 3.1 1.6 3.2 284.2 
19 90.9 3.5 2.0 3.6 281.7 
20 90.7 3.9 2.0 3.4 282.0 
    Mean 284.7 
    SD     2.4 
 
 
aScanned and analyzed PR-stained IHC slides from random sections throughout the depth of 
one T47D cell bock. 
 
bHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
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Table 3: Summary of FFPE Cell Line Block IHC HScores in Different IHC Runsa 
ER 	  	  
	   	   	  
 Run 13 TMA
b  Special CLMAb  
FFPE Cell 
Blockc   Final TMA
d   
Cell line     Number  
                of slides 46 40 3-9 40   
AU-565 54 ± 41 47 ± 47 3 ± 3 15 ± 14   
BT-474 155 ± 56 167 ± 71 108 ± 19 58 ± 17  
HBL-100 55 ± 46 30 ± 39  8 ± 1 0 11 ± 15  
HS-578T 46 ± 36 39 ± 40 11 ± 9 7 ± 9  
MCF-7 238 ± 38 250 ± 36 182 ± 40 187 ± 29  
MDA-MB-231 61 ± 53 49 ± 46  3 ± 4 19 ± 18  
MDA-MB-435 51 ± 46 45 ± 52 9 ± 11 17 ± 17  
SKBR-3 64 ± 50 --- 1  ± 1 14 ± 14  
T47D 208 ± 57 224 ± 56 160 ± 42 160 ± 42  
PR      
 Run 13 TMA
c  Special CLMAc  
FFPE Cell 
Blockd  Final TMA
e  
Cell line     Number  
                of slides 41 40 2-6 40  
AU-565 53 ± 45 48 ± 60 7 ± 3 15 ± 14  
BT-474 275 ± 16 213 ± 47 243 ± 19 237 ± 12  
HBL-100 50 ± 42 34 ± 43 8 ± 7 21 ± 29  
HS-578T 42 ± 33 36 ± 36 28 ± 10 16 ± 22  
MCF-7 49 ± 43 41 ± 50 3 ± 2 24 ± 21  
MDA-MB-231 42 ± 41 44 ± 50 15 ± 5 21 ± 21  
MDA-MB-435 158 ± 41 142 ± 47 110 ± 41 143 ± 19  
SKBR-3 64 ± 45 --- 7 ± 5 14 ± 13  
T47D 294 ± 6  287 ± 30 285 ± 6 282 ± 6  
HER2      
 Run 13 TMA
c  Special CLMAc  
FFPE Cell 
Blockd  Final TMA
e  JGH Controlf  
Cell line     Number  
                of slides 34 35 4-9 40 54 
AU-565 264 ± 73 247 ± 82 268 ± 13 263 ± 7 275 ±19 
BT-474 279 ± 10 210 ± 94 265 ± 3 250 ± 9 --- 
HBL-100 86 ± 88  15 ± 22 46 ± 15 2 ± 2 --- 
HS-578T 79 ± 73 25 ± 22 7 ± 4 1 ± 1 --- 
MCF-7 177 ± 79 45 ± 52 66 ± 14 10 ± 8 --- 
MDA-MB-231 76 ± 88 17 ± 27 7 ± 5 1 ± 2 0.3 ± 0.4 
MDA-MB-435 51 ± 77 21 ± 21 0 ± 0 0 ± 0 --- 
SKBR-3 294 ± 13 --- 255 ± 26 269 ± 5 --- 
T47D 220 ± 67 97 ± 66 170 ± 17 142 ± 30 --- 
aHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
bResults expressed as average HScore ± SD.  
cRun 13 and Special TMA, CLMA created for cIQc EQA runs, containing cell line and tissue cores. 
dFFPE Cell blocks, the formalin-fixed paraffin-embedded cell line blocks stained at SCH Laboratory. 
eFinal TMA,CLMA created for in-laboratory PT at SCH Laboratory, containing cell line and tissue cores.  
fJGH Controls, TMA control slides created at JGH for HER2 IHC.  
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Figure 3: Erroneous IA of Stained, Folded or Damaged TMA Cores. Circled areas denote 
where IA-measured stain intensities are incorrectly measured. The differences in colour 
between the undamaged portion of the core and the damages areas in IA analysis indicate 
differently measured stain intensities. IA images (B, D and F) use colour to indicate stain 
intensities (0, blue, 1+, yellow, 2+, orange, 3+, red). A, IA image of a folded nuclear IHC-stained 
core; B, incorrect IA analysis of image A; C, IA image of a folded membranous IHC-stained 
core; D, incorrect IA analysis of image C; E, IA image of a damaged nuclear IHC-stained core; 
F, incorrect IA analysis of image E. 
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negative by participating laboratories. This information was submitted together with the 
stained slides to the cIQc Program to assess IHC-interpretation skill as a part of the 
EQA evaluation. Slides stained by participating laboratories for ER, PR, and HER2 were 
visually assessed by cIQc pathologists and technologists in Toronto, Ontario in October 
2010 (so-called "expert assessment"). Participating laboratories with acceptable 
staining (≥90% agreement with reference results and/or a κ ≥ 0.8) received a passing 
grade from the cIQc Program. 
cIQc Program results are summarized using a garratogram. In a garratogram, tissue 
samples showing positive staining are denoted with red squares, negative results are 
denoted with white squares and unacceptable or missing samples are denoted as 
yellow squares. When the results of all cores for all participating laboratories are lined 
up beside those for reference laboratories, the cores that are not properly stained are 
easily observed. Figure 4 is an example of selected slides from Run 13 ER 
garratograms. Cell line samples were not included in the garratogram because their 
results were measured with IA for the purpose of this study and were not a part of the 
PT program.  
The second “Special” cIQc run CLMA contained the newly created FFPE cell lines 
and FFPE breast carcinoma cores donated by JGH. Slides were returned from 40, 40 
and 35 laboratories for ER, PR and HER2, respectively. Of these slides, 32 could be 
measured by IA for ER, 26 for PR and 32 for HER2.  Unfortunately, the donated tissue 
cores were suboptimal and did not adhere well to the slides, resulting in unusable tissue 
IA results from this run. Consequently, only Run 13 results were available to assess 
how results obtained by participating laboratories with tissue cores compared with that 
of cell lines. The Special cIQc Run cell line cores results were utilized differently. IA 
HScores and LSRSRs of all cell lines were used to compare PT performance between 
two consecutive cIQc Program runs (Run 13 and Special Run).  
3.1.2.1 Using IA data for PT performance evaluation: LSRSR and HScore 
 
Slides from PT were stained by many different laboratories using differing methods. 
With no standardized IHC protocols or controls, a wide range in measured IHC results is 
often  detected  in  most  PT  schemes/runs.  The results  of  PT  are  usually  evaluated  
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Figure 4: Garratogram of Expert Assessment Results from cIQc ER Run 13. 
Garratograms allow for visual comparison of expert pathologist assessment of slides 
stained by an FDA-approved kit and by reference laboratories to expert pathologist 
assessment of EQA slides stained by participating laboratories. Laboratories considered 
successful at EQA garratogram evaluation have > 90% agreement with reference 
slides. Red squares, positive stain (>1% cell nuclei staining); White squares, negative 
staining; Yellow squares, Unacceptable/missing cores. Results are shown for 39 of the 
total 58 participating laboratories. 
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qualitatively and only partly quantitatively, since no measuring takes place. 
Consequently, the parameters of test performance (statistical analyses and 
comparisons of sensitivity and specificity) that are traditionally used in quality 
management are impractical and, most of the time, impossible. Specific laboratory 
information was unavailable to stratify EQA laboratories into sub-groups (by HIER 
method, antibody or reagents used) for further comparison. LSRSR and graphical 
methods were examined as useful methods to better quantify IHC PT results. 
3.1.2.1.1 LSRSR analysis and calculation 
 
In our 2011 publication, LSRSR was proposed as a new ratio for the monitoring of 
EQA IHC performance 161. The closer an LSRSR is to a value of 1, the closer the 
performance of the laboratory is to that of the reference laboratory. Initial detailed 
statistical analysis of Run 13 HScore LSRSRs was carried out with one reference 
laboratory (cIQc Laboratory 114), which showed the most consistent performance, from 
one run to another, from inception of the cIQc Program. The LSRSR performance of 
laboratories was divided into ranges of Low (<0.8), medium (0.8-1.2) and high (>1.2).  
Run 13 ER sensitivity and specificity were determined for single-reference LSRSR. 
LSRSR was compared to the garratogram scoring for each tissue core of each slide. 
Laboratory 114 results were selected by the cIQc Program as the true positive and 
negative values for both calculations. Calculation of LSRSRs for all cores on all slides 
was time consuming and labour intensive. By this approach, five laboratories performed 
unsatisfactorily (<80% sensitivity) for Run 13 ER tissue cores.  
Although it was not statistically significant, it interesting to note that >91% (14 cores) 
of the poorly stained cores in Run 13 ER EQA (as rated by expert assessment) have 
single-reference LSRSRs outside of 0.8-1.2 (range, 0-5; average, 0.6). These initial 
calculations demonstrated how LSRSRs are complementary to expert assessment 
results, and can be used instead of expert assessment when the methods applied to 
generate LSRSRs are properly validated. Although analysis with garratograms appears 
simpler and less labour-intensive than determining single-reference LSRSRs, the effort 
and expertise required to generate garratograms is greater than the calculation of 
LSRSRs when a smaller number of samples is used for evaluation. 
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3.1.2.1.2 Using IA HScore to graphically demonstrate PT performance: boxplot 
and histograms  
 
Box plots and histograms offer excellent simple visual summaries of EQA HScore 
results. cIQc Run 13 results were plotted for each core of each slide from all 
participating laboratories. cIQc results were compared to LSRSR results for Run 13 
using box-plots and histograms. LSRSR graphs are very similar to HScore graphs when 
used in this manner. While LSRSRs are more efficient in showing variation with respect 
to a reference value, HScores are more convenient, time-wise. Consequently, HScores 
were used for these visual comparisons. 
Histograms and boxplots visualize individual EQA laboratory performance with 
respect to the entire group. Laboratories with poor performance had HScores far from 
the mean of the results. A low or high LSRSR reflects this poor performance. It is 
possible to distinguish both poor and adequately performing laboratories on a histogram 
or boxplot of EQA results for TMA cores. Figure 5 shows an example of laboratories 
with a good and a poor LSRSR, using boxplots and histograms for an individual TMA 
core.   
3.1.3 Optimal use of EQA LSRSR: multiple-reference evaluation of cIQc EQA runs 
 
Even the best reference laboratory in the cIQc Program showed some variation in 
IHC results. The limitation of using single-reference LSRSR is in the fact that the 
samples used for testing are human tumors, which always show biological variation 
within a tissue core.  Consequently, for this study, a different approach was used to 
partly compensate for this tissue heterogeneity. A small number of representative, 
diagnostic cores were evaluated from slides stained by a group of reference 
laboratories. A small number of tissue cores with informative HScores were selected, 
since the majority of high expressing and low/negative expressing samples were not 
contributory in our analyses. This multiple-reference approach was used for the 
remainder of this research. Once LSRSRs for all reference laboratories and cores were 
plotted,  the  minimum  and  maximum  acceptable  LSRSRs  were  identified.  Example 
graphs of multiple-reference LSRSR acceptable ranges for cell line and tissue cores in 
Run 13 ER EQA are shown in Figure 6. 
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Figure 5: Box Plot and Histogram Plots of HScores of One Tissue Core for a Good 
and a Poor Performing Laboratory. Box plots and histograms were used to 
summarize EQA HScore results from cIQc Run 13 of ER for all participating 
laboratories. HScores for a good and a poor performing laboratory are indicated by 
arrows in relation to the group results. A, a good performing laboratory; B, a poor 
performing laboratory.  
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Figure 6: LSRSR Range Assessment for Cell Line and Tissue Cores in Run 13 ER 
EQA. Six representative cores were selected and the HScores from five reference 
laboratories were used to calculate LSRSRs for these cores. The minimum and 
maximum of these reference laboratory LSRSRs are the acceptable LSRSR range for 
the EQA performance rating of all participating laboratories in Run 13 ER. A, LSRSR 
range for cell line reference cores; B, LSRSR range for tissue reference cores.  
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Representative cores with mean HScores in the linear diagnostic IHC range were 
selected for Run 13 and Special Run ER, PR and HER2. Six reference laboratories 
(101, 102, 114, 115, 126, 129) were selected based on consistent previous EQA cell 
line cores and acceptable LSRSR ranges defined for each IHC stain and core type (cell 
line or tissue).  
3.1.3.1 LSRSR reference ranges for cIQc EQA runs 
3.1.3.1.1 Run 13 LSRSR assessment of PT performance 
 
For ER and PR, six cell line and tissue cores were selected by mean HScore. For 
HER2, five Run 13 cell line and tissue cores were selected by mean HScore. HER2 cell 
line core selection was problematic because most FFPE cell lines stained very low 
(HScore <20) or high (HScore >150). Consequently, two HER2 cores with HScores 
above 100 were selected for LSRSR calculations. Cell lines AU-565, HBL-100, HS-
578T, MCF-7, MDA-MB-435 and MDA-MB-231 were used for evaluation of ER (mean 
HScores, 60-98). Cell lines AU-565, BT-474, HBL-100, HS-578T, MDA-MB-231, MDA-
MB-435 and SKBR-3 were used for evaluation of PR (mean HScores, 43-73). Cell lines 
AU-565, HS-578T, MCF-7, MDA-MB-435, and T47D were used for HER2 evaluation 
(mean HScores, 50 - 259). The selected ER, PR and HER2 tissue cores had mean 
HScores of 51- 93, 41 - 105 and 35 – 103, respectively. 
In each analysis, one or more reference laboratories were excluded. One laboratory 
did not participate in Run 13. Other laboratories were excluded from ER, PR and HER2 
analyses due to extreme LSRSR values (as per Section 2.6.3.4). The number of 
reference laboratories, representative cores and acceptable reference LSRSR ranges 
for Run 13 ER, PR and HER2 cell line and tissue cores can be found in Table 4. 
Initially, LSRSR was applied as a “pass/fail” measurement, with acceptable 
laboratory performance defined as having >80% of the selected array cores with 
acceptable LSRSR values. For ER and PR, cell line LSRSR ranges for reference 
laboratories were smaller and more discriminatory, resulting in a lower percentage of 
acceptably performing laboratories.   In contrast, for HER2,  tissue LSRSR ranges were  
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Table 4: Run 13 Cell Line Core and Tissue Core LSRSRa Reference Rangesb Used 
in EQA Analysis of Performance. A, LSRSR reference calculation data. B, IA LSRSR 
evaluation of overall laboratory performance as a pass/fail measurement. 
 
 
 
 
 
aLSRSR; Laboratory Score: Reference Method Score Ratio, calculated from IA HScore values.  
 
bLSRSR reference ranges are calculated using the average HScore values of the designated reference laboratories 
for five or six representative cores.  
 
cReference Laboratories are selected by cIQc for each run based on previous high quality of IHC staining. Not all 
laboratories could be evaluated for all stains due to loss of tissue in representative cores.  
 
dRepresentative cores are selected with HScores between 40 and 100 so that staining levels are in an optimal linear 
range. 
 
eCell line LSRSR ranges are more stringent than tissue LSRSR ranges due to tissue core heterogeneity. More 
laboratories were acceptably rated when the less stringent tissue LSRSR was used.  
 
fHER2 LSRSR ranges are the opposite in stringency to those for ER and PR: Tissue LSRSR are more stringent. Lack 
of ideal diagnostic HER2 reference cores may be the cause.  
 
g Some core loss occurred. Consequently, a number of laboratories were evaluated with as many of the six 
representative cores that remained on the slide. LSRSR values were calculated from no less than three and no more 
than five reference laboratory HScores. 
 
hAcceptable laboratories had ≥ 80% of their calculated LSRSR values fall with the reference LSRSR ranges for the 
representative cores. Passing criteria is >80% of the six representative cores having an LSRSR within the LSRSR 
reference range.  
 
  
 
 Cell Line Cores Tissue Cores 
ER PR HER2 ER PR HER2 
Reference laboratoriesc 4 3 4 4 4 4 
Representative coresd 6 6 5 6 6 5 
IA LSRSR reference 
ranges 0.47-1.39 
e 0.35-1.67 e 0.27-2.05 f 0.49-1.72 e 0.24-2.05 e 0.33-1.73 f 
 
Value 
ER PR HER2 
Tissue  Cell  Tissue  Cell  Tissue  Cell  
Slides received from laboratories 46 46 45 45 37 37 
TMA sample cores measureable by IAg 42 44 52 48 34 34 
Laboratories measured with IA 39 46 41 41 34 33 
LSRSR acceptable laboratoriesh 17 16 28 19 23 24 
% LSRSR acceptable laboratoriesh 44% 35% 68% 46% 68% 73% 
Laboratories acceptable by both cell and 
tissue LSRSRh  12 19 16 
Laboratories unacceptable by both cell and 
tissue LSRSRh 12 6 3 
A. 
B. 
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more stringent, with a lower percentage of laboratories given an acceptable 
performance evaluation.  Tissues or cell lines with high HScores were less sensitive for 
detecting variation of IHC staining. Cores with very low HScores were more variable in 
LSRSR analysis due to the larger relative differences in the small values used for 
LSRSR calculation. Not all laboratories with acceptable performance were rated as 
such by both cell line and tissue LSRSR. Pass/fail results are summarized in Table 4.  
3.1.3.1.2 Run 13 cIQc assessment of PT performance  
 
cIQc Program EQA evaluation of Run 13 was presented using two methods: the 
calculation of agreement of tissue core staining with reference staining and a 
comparison of laboratory stain results to reference stain results using κ values. 
Calculated agreement with a reference (and evaluation by κ) concluded that 60% 
(69%), 75% (73%) and 95% (93%) of laboratories had acceptable performance (as 
defined by international standards for these particular tests) for ER, PR and HER2 IHC, 
respectively. Twelve, three and two laboratories had sub-optimal performance (80-90% 
concordance with reference) for ER, PR and HER2, respectively. The cIQc Program 
notified laboratories of any unacceptable performance. Suggestions for improvement to 
submitted laboratory IHC protocols were given, whenever possible. Detailed cIQc Run 
13 assessment results are in Supplemental Table 2. 
3.1.3.1.3 Comparison of Run 13 cIQc and LSRSR evaluation  
 
Run 13 LSRSR results were compared to cIQc EQA assessment results. A figure 
was assembled, similar to a garratogram, to visually compare cIQc and LSRSR 
performance data. In Figure 7, examples of laboratories with agreeing cIQc and LSRSR 
results (both acceptable and unacceptable) and examples where the cIQc and LSRSR 
results disagree are shown. Table 5 then summarizes the overall agreement in ER, PR 
and HER2 staining by the two methods. LSRSR reference ranges for ER and PR cell 
lines appear to be more discriminatory than cIQc evaluation. In contrast, LSRSR 
reference ranges for HER2 tissues were more discriminatory than cell lines, and more 
discriminatory than cIQc expert assessment evaluation. 
Cell line and tissue cores were examined to see whether the same types of 
unacceptable errors in staining were observed for a laboratory using LSRSR evaluation  
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Figure 7: A Visual Comparison of Run 13 ER Cell Line and Tissue Core IA LSRSRa 
and cIQc Assessmentb Results.  Selected examples of each type of agreement and 
disagreement are shown.  
 
The top row of the figure indicates cIQc laboratory κ results; Light green, acceptable 
cIQc laboratory performancec; Light red, unacceptable cIQc performance. Remaining 
rows include IA LSRSR laboratory results for each cell line, with each laboratory as a 
separate column; Dark green, acceptable LSRSR performanced; Dark red squares, 
unacceptable LSRSR performance, with “H” and “L“ unacceptable LSRSR values above 
and below acceptable the LSRSR range, respectively. Grey squares were inferior 
quality cores that could not be measured by IA. 
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ER κ   0.74 0.87 0.87 0.69   1.00 0.82 0.73 0.94 0.81   
 
 
 
aLSRSR, Laboratory Score: Reference Method Score Ratio, calculated from IA HScore values.  
 
bcIQc assessment calculated from comparison of participant and cIQc pathologist-scored garratogram 
results 
 
cAcceptable cIQc performance; 90% correct staining results and Cohen’s κ ≥0.8 between laboratory IHC 
results and cIQc IHC-assessed staining results. Poor or unacceptable κ results were <0.8. 
 
dAcceptable IA LSRSR performance; LSRSR of laboratory is within acceptable reference LSRSR range. 
LSRSR reference ranges are calculated using the average HScore values of the designated reference 
laboratories for five to six representative cores. 
 
Poor 
 Kappa 
Acceptable 
Kappa 
  Core 
              Laboratory 
  Core 
               Laboratory 
Same Results                             Different Results 
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Table 5: Comparison of Acceptablea and Unacceptableb Run 13 EQA Results as 
Measured by IA LSRSRc and cIQc Assessmentd.  
 
 
 
ER PR HER2 
cIQc / LSRSR Cell Line Tissue Cell Line Tissue Cell line Tissue 
Ne 46 39 41 41 33 34 
Acceptable cIQc / 
Acceptable LSRSR 10 (22%)  10 (26%) 17 (41%) 22 (61%) 21 (64%) 22 (65%) 
Acceptable cIQc/ 
Unacceptable LSRSR 24 (52%) 18 (46%) 15 (37%)  7 (17%) 9 (27%) 9 (26%) 
Unacceptable cIQc/ 
Acceptable LSRSR 6 (13%) 7 (18%) 2 (5%) 3 (7%) 3 (9%) 1 (3%) 
Unacceptable cIQc / 
Unacceptable LSRSR 6 (13%) 4 (10%) 7 (17%) 6 (15%) 0 (0%) 2 (6%) 
 
 
aAcceptable cIQc performance ≥ 90% correct staining results and κ ≥0.8 when compared to 
cIQc assessment garratogram values.  
 
bAcceptable IA LSRSR performance, IA LSRSR of laboratory has 80% of cores within 
acceptable reference LSRSR range. LSRSR reference ranges are calculated from the average 
HScore values of the designated reference laboratories for five to six representative cores. 
 
cLSRSR; Laboratory Score: Reference Method Score Ratio, calculated from IA HScore values.  
 
dcIQc assessment calculated from comparison of participant and cIQc pathologist scored 
garratogram results 
 
eN; Number of laboratories. 
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for both core types. Generally, there was an agreement between the cell line and tissue 
core evaluations for each laboratory. For tissue cores, 20 of 21, eight of eight and two of 
ten unacceptably performing laboratories had LSRSRs below the acceptable reference 
range, for ER, PR and HER2, respectively. For cell line cores, 23 of 30, 18 of 22 and 
five of nine unacceptably performing laboratories were below acceptable range for ER, 
PR and HER2, respectively. There were twelve, six and zero laboratories that 
performed unacceptably, in the same manner (either both high or both low), for both cell 
line and tissue LSRSRs for ER, PR and HER2, respectively. In all cases, the 
unacceptably performing ER and PR results were below acceptable range (false 
negative), indicating problems with test sensitivity. The six laboratories with 
unacceptable PR LSRSR results had unacceptable PR results by cIQc κ evaluation.  
 There were only three laboratories with disagreement in the type of unacceptable 
performance for their reference cores (i.e., staining both above and below the 
acceptable LSRSR ranges), suggesting problems with both sensitivity and specificity. 
For ER and HER2, one laboratory showed disagreement by having an unacceptably 
high cell line LSRSR and unacceptably low tissue LSRSR. For PR, one laboratory had 
one tissue core above and one tissue core below the acceptable LSRSR range. 
Examination of individual slides clarified these LSRSR disagreements as non-critical. 
The questionable ER and HER2 tissue cores were positively stained overall and in 
agreement with cIQc reference and κ scoring. Upon examination, the over-staining PR 
core did not contain any tumor tissue and was therefore excluded from analysis.  
When an LSRSR was unacceptably high or low for laboratories rated acceptable by 
cIQc κ, the stained cores were visually examined and confirmed as positively stained for 
ER and PR, despite poor LSRSR results. This, together with the above results, 
demonstrates the use of LSRSRs as a calibration and monitoring tool.  
3.1.3.2 Special Run LSRSR assessment of cell line EQA performance 
 
Acceptable LSRSR ranges were calculated for Special EQA Run cell line cores to 
compare performance of participating laboratories over two consecutive EQA runs. Due 
to tissue loss, there were no sufficient tissue cores for cIQc expert assessment for this 
run. LSRSR reference ranges were defined using cell lines AU-565, HBL-100, HS-578T 
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MDA-MB-231 and MDA-MB-435 for ER; cell lines AU-565, BT-474, HBL-100, MDA-MB-
231, and MDA-MB-435 for PR; and cell lines BT-474, HS-578T, MCF-7, MDA-MB-231, 
and T47D for HER2. Results from four reference laboratories were available. The 
acceptable LSRSR ranges were 0.69-1.50, 0.28-1.84 and 0.21-2.05 for ER, PR and 
HER2, respectively. There were nine, eleven and ten of 39 total participating 
laboratories with acceptable performance by LSRSR for ER, PR and HER2, 
respectively.  
3.1.3.2.1 Run 13 and Special Run LSRSR EQA assessment comparison  
 
Cell line LSRSRs for Run 13 and Special Run were compared to each other. 
LSRSR analysis identified subtle changes in IHC-staining results as a result of higher IA 
resolution and cell line biological homogeneity. Cell lines present in both runs with 
similar HScores were used for comparison. Laboratories with unacceptable 
performance, by cIQc κ assessment, in Run 13, were examined to determine whether a 
change/improvement of performance was observed with LSRSR in the next Special 
cIQc Run. Summary figures were assembled for comparison of ER, PR and HER2 
results in the same manner as for Run 13 LSRSR and cIQc κ results. Figure 8 is a 
composite figure demonstrating this comparison, with examples of laboratories with no 
shift in LSRSR and ones with LSRSR shift in the subsequent run.  
The ER reference samples compared between Run 13 and Special Run were cell 
lines AU-565, HBL-100, HS-578T, MDA-MB-231 and MDA-MB-435, with HScore 
Ranges of 60-78 and 56-93, respectively. The PR reference samples compared 
between Run 13 and Special Run were cell lines AU-565, HBL-100, MDA-MB-231, and 
MDA-MB-435, with HScore Ranges of 71-76 and 31-50, respectively. The HER2 
reference samples compared between Run 13 and Special Run were cell lines BT-474 
and T47D, with HScore Ranges of 259-253 and 58-122, respectively. There were 32, 26 
and 26 laboratories with IA scorable results for both EQA runs for ER, PR and HER2, 
respectively. 
3.1.3.2.2 Observed change in performance between subsequent runs (“Run 13” to 
“Special Run”) 
 
Over  50%  of  laboratories  who  were  informed  about  their  unacceptable  cIQc  κ  
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Figure 8: Using IA LSRSRa to Observe Performance Change Between EQA Runs: A 
Comparison of Run 13 and Special Run ER Cell Line Evaluation Results. Summary of the 
laboratories with an unacceptable cIQc evaluationb in Run 13 which showed a measurable 
change in IHC-stain performance by IA LSRSR for the next cIQc Special Run. Selected 
examples of each type of agreement and disagreement are shown.  
 
The top row of the figure indicates cIQc laboratory κ results; Light green, acceptable cIQc 
laboratory performancec; Light red, unacceptable cIQc performance. Remaining rows include IA 
LSRSR laboratory results for each cell line, with each laboratory as a separate column; Dark 
green, acceptable LSRSR performanced; Dark red squares, unacceptable LSRSR performance, 
with “H” and “L“ unacceptable LSRSR values above and below acceptable the LSRSR range, 
respectively. Grey squares were inferior quality cores that could not be measured by IA. 
 
 
 
 
 
 
aLSRSR, Laboratory Score: Reference Method Score Ratio, calculated from IA HScore values.  
 
bcIQc assessment calculated from comparison of participant and cIQc pathologist scored garratogram 
results 
 
cAcceptable cIQc performance; 90% correct staining results and Cohen’s κ ≥0.8 between laboratory IHC 
results and cIQc IHC assessed staining results.  Poor or unacceptable κ results were <0.8. 
 
dAcceptable IA LSRSR performance; LSRSR of laboratory is within acceptable reference LSRSR range. 
LSRSR reference ranges are calculated using the average HScore values of the designated reference 
laboratories for five to six representative cores. 
  
LSRSR Range = 0.47-1.39                              
   101 102 160   124 132   106 107 133   113 123 151 
Average 
HScore 
AU-565    L H   L L       H   L     72 
HBL-100    L H   L             L   H 73 
HS-578T    L H   L             L     60 
MDA-MB-231    L H   L         H   L   H 78 
MDA-MB-435    L H   L             L     68 
                                 
LSRSR Range = 0.69-1.50 
                  
   101 102 160   124 132   106 107 133   113 123 151 
Average 
HScore 
AU-565    L H   L       L L       L 93 
HBL-100    L H   L L   H L L     H   56 
HS-578T    L H   L       L     H   L 71 
MDA-MB-231    L H   L     H L       H   84 
MDA-MB-435    L H   L     H L       H   75 
                    
ER κ 0.88 0.95 0.94   0.69 0.78   1.00 0.95 0.81   0.67 0.79 0.47  
    Acceptable Kappa  Poor Kappa   Acceptable Kappa   Poor Kappa  
    Change in overall performance      No change in overall performance 
  Core 
                  Laboratory 
  Core 
                Laboratory 
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performance in Run 13 changed their performance in the Special Run for ER, PR and 
HER2. These were fully detectable by LSRSR while visual inspection was insensitive 
and uninformative. Table 6 summarizes the change in LSRSR measured stain 
performance between the Run 13 and Special EQA Runs. For ER, the LSRSR-
measured change in stain performance for κ unacceptably performing laboratories was 
statistically significant (by Chi-squared evaluation of change in response) when 
compared to changes observed in κ acceptably performing laboratories. This 
demonstrates the use of LSRSR to measure IHC performance and method correction. 
There were too few HER2 unacceptable laboratories for statistical inference.  
3.2 Daily positive controls monitored by IA through Levey Jennings QC charts. 
 
Currently used, tissue-based, on-slide breast marker IHC controls for ER, PR and 
HER2 QA run from four Canadian hospitals were evaluated with IA. IA HScores of 
consecutive slides were plotted to create Levey-Jennings QC charts, as previously 
described. CLMAs containing FFPE tissue and cell lines were also created and stained 
for ER, PR and HER2 at SCH and for HER2 at JGH.  
3.2.1 IA of currently used, tissue-based controls in clinical IHC 
 
The functionality of the different tissue types used in the above on-slide IHC 
controls was compared. Consecutive, IA-measured and plotted sets of control slides 
came from the same control blocks. Breast tissue and/or endometrium tissues were 
used for ER and PR controls. Breast tissue was used for HER2 controls. IA HScore 
Levey-Jennings QC charts were examined to comment on best practise for 
measurement and application. Statistically significant differences in SD from the mean 
between whole and partial control IA HScore SD were measured with an F-test.  
Trending in HScore could be observed over time, demonstrating IA HScore QC 
chart functionality. QC Charts were used for multiple comparisons of these current on-
slide clinical tissue controls. 
3.2.1.1 Effect of the area of IA analysis: whole versus partial analysis  
 
On-slide tissue controls for ER, PR and HER2 were examined to see if IA of an 
entire  control  was  necessary  for  QA  purposes.    The  entire  control  and  a  smaller  
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Table 6: Using LSRSRa to Calibrate EQA IHC Performance: Change in IHC-Stain 
Performance in Special Run After an Unacceptable cIQc Run 13 Performanceb. 
Special Run results were examined for a change in LSRSRc measured performance 
from Run 13. Laboratories with a poor Run 13 performance made more changes in their 
staining, as measured by changing IA LSRSR results in the next EQA Special Run. 
 
 Acceptable (κ ≥ 0.8) Unacceptable (κ <0.8)  % Change LSRSR Results 
Stain LSRSR Improvement No change 
LSRSR 
Improvement No change  Stain κ ≥ 0.8 κ <0.8 
ER 6 18 4 4  ER 25% 50% * 
PR 8 11 4 3  PR 42% 57%  
HER2 10 13 2 0  HER2 43% 100%  
 
aLSRSR; Laboratory Score: Reference Method Score Ratio, calculated from IA HScore values.  
 
bAcceptable Run 13 EQA performance is rated as a κ ≥ 0.8 between laboratory and cIQc IHC 
results.  
 
cLSRSR reference ranges are calculated using the average HScore values of the designated 
reference laboratories for five to six representative cores. 
 
*Changes in performance between the two EQA runs are statistically significant in cIQc 
unacceptably performing laboratories when compared to LSRSR changes occurring in cIQc 
acceptably performing laboratories. This suggests a calibration in methodology between runs. 
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representative portion of the same control were analyzed with IA from the same 
scanned image. QC charts for whole tissue and partial tissue IA HScore were compared. 
Whole IA HScore QC charts were observed to be more stringent, with smaller SD, for all 
locations and tissue types. The calculated difference in SD between whole and partial 
control was significantly different for many of the tissue controls for ER, PR and HER2 
(Table 7, 8 and 9, respectively). ER controls had the largest number of significantly 
different controls. The QC chart HScore SD of all the partial control samples were larger 
than those of the whole control samples, regardless of the size of the smaller portion 
analyzed. An example of a control from JGH with corresponding QC charts, showing the 
difference between whole and partial section results, can be seen in Figure 9.  
3.2.1.2 Effect of control tissue type  
 
Breast and endometrium tissues were used separately, and in combination, as ER 
and PR IHC controls. Breast tissue was used as an HER2 IHC control. IA results for 
each type of on-slide control tissue were compared. Statistically significant differences 
in SD between whole and partial sample IA HScore SD were measured with an F-test. 
Significant differences were observed in SD for each tissue type in Tables 7, 8 and 9, 
for ER, PR and HER2, respectively. Although Ontario endometrium controls had no 
significant SD difference between whole and partial QC charts, a larger sample set is 
required to comment more definitively. No tissue was identified as a superior control. 
3.3 Building better positive controls: comparison of new cell line-based controls 
to current tissue-based controls  
 
A cIQc panel of pathologists visually selected low to intermediate staining FFPE cell 
lines from Run 13 cell line slides stained by reference laboratories. For ER, AU-565, 
HS-578T and MDA-MB-231 cells were selected, with MCF-7 cells selected as a high 
staining positive control. For PR, AU-565 and MCF-7 cells were selected, with T47D 
cells selected as a high staining positive control. For HER2, MCF-7 and MDA-MB-231 
cells were selected, with AU-565 cells selected as a high staining positive control. For 
ER, PR and HER2, three, two and two cell lines selected by pathologists were also 
selected for use with IA, respectively.  
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Table 7. Description and IA Analysis of ER On-Slide IHC Controls. 
     
ER Group Na Whole or Part 
Mean       
HScoreb ± SD  
F-test               
p-value 
Saskatoon  8 Whole 66 ± 14  <0.01 
(breast)   Part 158 ± 22  
 9 Whole 67 ± 12  <0.01 
  
  Part 134 ± 35  
39 Whole 40 ± 42 <0.01 
  Part 77 ± 71  
  55 Whole 104 ± 33 <0.01 
    Part 123 ± 68   
  15 Whole 57 ± 36 <0.01 
   Part 102 ± 67  
  6 Whole 78 ± 16   0.36  
   Part 121 ± 8  
Ontario  11 Whole 192 ± 15  0.6 
(endometrium)   Part 195 ± 14  
Quebec  30 Whole  89 ± 12  <0.01 
(endometrium  Part 151 ± 27  
and breast) 15 Whole 82 ± 10  <0.01 
    Part 134 ± 17  
Alberta  71 Whole 76 ± 11  <0.01 
(breast)   Part 218 ± 13  
 
 
aN, number of slides for that unique control. 
 
bHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
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Table 8. Description and IA Analysis of PR On-Slide IHC Controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aN, number of slides for that unique control. 
 
bHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
 
     
PR Group Na Area Mean       HScoreb ± SD  
F-test               
p-value 
Saskatoon  11 Whole 105 ± 11 <0.01  
(breast) 
 
  Part 215 ± 18  
7 Whole 223 ± 12 0.31 
   Part 219 ± 5   
  7 Whole 219 ± 5 0.06 
   Part 208 ± 42  
  13 Whole 232 ± 5  <0.01  
    Part 113 ± 19  
  29 Whole 189 ± 13 0.14 
   Part 114 ± 19  
  43 Whole 228 ± 11  0.01  
    Part 130 ± 28  
Ontario  9 Whole 187 ± 17 0.96 
(endometrium)   Part 187 ± 18  
Quebec  27 Whole 90 ± 12 0.39 
(endometrium    Part 64 ± 17  
and breast) 15 Whole 87 ± 25 0.78 
    Part 38 ± 17  
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Table 9. Description and IA Analysis of HER2 On-Slide IHC Controls.  
    
HER2 Group Na Area Mean       HScoreb ± SD  
F-test               
p-value 
Saskatoon 
 (breast) 
18 Whole 104 ± 15 <0.01 
  Part  168 ± 56  
89 Whole 112 ± 15 0.35 
 Part 144 ± 17  
  18 Whole 120 ± 24  0.35 
    Part 148 ± 20  
Quebec  58 Whole 73 ± 22  0.14 
(breast)   Part 66 ± 20  
Alberta 26 Whole 121 ± 22  0.39 
(breast)  Part 177 ± 28  
  25 Whole 75 ± 19  0.01 
    Part 23 ± 10  
  10 Whole 54 ± 9 0.9 
   Part 15 ± 9  
  15 Whole 128 ± 14 <0.01 
    Part 83 ± 25  
 
aN, number of slides for that unique control. 
 
bHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
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Figure 9: A Comparison of Whole Section and Partial Section QC Charts. IA HScore values 
of thirty consecutive IHC-stained ER controls were plotted to create a QC chart. Orange lines denote two 
SD from the mean HScore. Red lines denote three SD from the mean HScore. Values falling outside of 2 
SD range indicate a need for recalibration of method and/or instrument. Values outside of 3 SD indicate 
the need for repeated testing because such results are unacceptable. A, a stained section of the mixed 
tissue ER control, composed of breast and endometrium tissue; B, the whole control IA HScore QC chart; 
C, the partial control IA HScore QC chart.  
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3.3.1 Using IA HScore for positive controls 
 
Final and JGH CLMA control blocks were examined as an alternative to the 
variability observed between and within tissue controls. There were 20 “Final” CLMA 
slides stained for ER, PR and HER2 and analyzed with IA. There were 54 JGH slides 
stained for HER2 and analyzed with IA. HScore QC charts were created for all slides for 
each IHC stain. Differences in SD from the mean HScore were compared for tissue and 
cell line cores of similar HScore with an F-test.  
3.3.1.1 Practical application of cell-line based controls in QC charts 
 
Final CLMA cell line QC charts were comparable in performance (similar trending 
patterns) to tissue QC charts. An observed difference in SD between cell line and tissue 
cores was statistically significant for some, but not all, of these comparisons. An 
example QC chart for a low ER HScore cell line core (MDA-MB-435), a medium PR 
HScore cell line core (MCF-7) and high HER2 HScore cell line (AU-565) are shown in 
Figure 10. This is the first direct observation of FFPE breast cancer cell line control QC 
charts, demonstrating their use as daily positive controls in QA. 
Normal laboratory practice is to prepare many control slides at once and store 
unstained slides at -80°C. CLMA slides were cut at the cIQc Program Laboratory. One 
was immediately stained for ER and a second slide was stored at -80°C for 30 days and 
then stained for ER. There were no significant measured decreases in ER HScore 
values for any cell line (paired t-test, Table 10). This preliminary work demonstrates that 
CLMA control slides can be sectioned and stored in the laboratory over time, in the 
same fashion as current controls, without sample degradation. 
3.3.1.1.1 Reproducibility and homogeneity of cell lines 
 
HScore values of duplicate cell line cores in “Final CLMA” were compared to each 
other by an unpaired t-test. No significant difference was observed between the 
HScores of duplicate cell line cores except for SKBR-3 for PR, and AU-565 and SKBR-3 
for HER2. These differing cell lines had either extremely low mean HScore (PR SKBR-
3, 14) or high mean HScore (HER2 AU-565, 263; HER2 SKBR-3, 269).  
Cell line QC charts showed IA reproducibility for multiple cores of the same cell line  
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Figure 10: QC Charts for Daily IA HScore Results from Final CLMA Cell Line Cores. 
HScore values of twenty consecutive IHC-stained cell line cores were plotted to create a QC 
chart. Orange lines denote two SD from the mean HScore. Red lines denote 3 SD from the 
mean HScore. Values falling outside of 2 SD range indicate a need for recalibration of method 
and/or instrument. Values outside of 3 SD indicate the need for repeated testing because such 
results are unacceptable. A, low HScore core; B, medium HScore core; C, high HScore core. 
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Table 10: Effect of -80°C Storage on IHC Staining of FFPE CLMA Slide Sections. 
HScorea of two slides, one stained by VGH immediately after preparation and one after 
30 days storage at  -80 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
 
 bDamaged core was incorrectly evaluated by IA to have an erroneously high HScore (156).  
  
Cell Line ID 0 days 30 days @            -80 °C 
AU-565 63 71 
BT-474 92 136 
HBL-100 67 73 
HS-578T 72 62 
MCF-7 250 269 
MDA-MB-231 45 87 
MDA-MB-435 38 69 
SKBR-3  (damaged)b 61 
T47D 198 204 
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over time when measured with IA. Trending and minimal variation in QC charts from two 
cores of the same intermediate cell line can be observed in Figure 11. This variation is 
reduced in lower staining cell lines, as shown in Figure 12.  Cell lines with high HScores 
had the smallest SD. Comparison examples of duplicate high cell line core QC charts 
are in Figure 13. Intermediate HScore controls showed more visible variation over time, 
resulting in better visualization of shifts and trends in staining from day to day. In 
contrast, demonstration of biological homogeneity by this method cannot be observed 
for tissues, because no two samples are alike. For all cores, any HScore values falling 
outside of  ±2 SD range indicate a need for recalibration of method and/or instrument. 
Values outside of 3 ± SD indicate the need for repeat testing because such results are 
unacceptable. 
3.3.1.2 On-slide tissue and cell line controls in ER, PR and HER2 IHC 
3.3.1.2.1 Final CLMA and JGH CLMA 
 
Cell line QC charts had smaller SD than tissue QC charts. For this reason, cell lines 
controls were more discerning for the measurement of variation in system calibration. 
Consequently, a number of samples that were borderline-acceptable in cell line QC 
charts were acceptable by tissue QC charts. A comparison of cell lines and tissues 
HScores in Final TMA is found in Table 11. The CLMA demonstrated that SCH 
Laboratory is performing well, as no cores failed QC chart evaluation by being outside 
of ± 3 SD from the mean during this study (data not shown).  
JGH selected two cell lines for visual verification of strongly positive (score, 3+) and 
low/negative (score, 0) HER2 staining. QC Charts from the cell line cores were matched 
with charts from two tissue cores of similar stain intensity (low/negative and strong). 
These results are shown in Figure 14. The low-staining cell line and tissue cores had 
HScore SDs of ± 0.5 and ± 0.2, respectively. The difference in low-staining core SD was 
statistically significant (F-test, p<0.01), with the HScore SD being slightly smaller for the 
cell line core. These small SD ranges were not sufficiently discriminatory for QC chart 
calibration use, even when graphed with a reduced Y-axis scale (data not shown). 
However, both negative- and strong- staining tissue and cell line samples produced very 
small  QC  chart  SD  ranges.    Such  small  QC  chart  SD  ranges  are  undesirable  in  
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Figure 11: Reproducibility of Medium HScore Cell Line Core QC Charts From the Final 
CLMA. QC charts of PR HScore IA values from two cores of MCF-7 cell lines in Final CLMA 
control slides. Slides are from twenty consecutive IHC runs at SCH. Orange lines denote two 
SD from the mean HScore. Red lines denote three SD from the mean HScore. A, CLMA core 7; 
B, CLMA core 18. 
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Figure 12: Reproducibility of Low HScore Cell Line Core QC Charts from the Final CLMA. 
QC charts of ER HScore IA values from two cores of MDA-MB-435 cell lines in Final CLMA 
control slides. Slides are from twenty consecutive IHC runs at SCH. Orange lines denote two 
SD from the mean HScore. Red lines denote three SD from the mean HScore. A, CLMA core 2; 
B, CLMA core 12. 
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Figure 13: Reproducibility of High HScore Cell Line Core QC Charts from the Final CLMA. 
QC charts of HER2 HScore IA values from two cores of AU565 cell lines in Final CLMA control 
slides. Slides are from twenty consecutive IHC runs at SCH. Orange lines denote two SD from 
the mean HScore. Red lines denote three SD from the mean HScore. A, CLMA core 3; B, 
CLMA core 13. 
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Table 11: Comparison of Cell Line and Tissue Core IA Mean HScorea b in the Final 
CLMA PT Control Block.  
 
Cell Line Core ER  PR  HER2 
AU-565 3 16 ± 4 17 ± 3 269 ± 1 
  13 16 ± 3 16 ± 3 257 ± 2 
BT-474 4 68 ± 10 241 ± 3 252 ± 2 
  14 65 ± 9 233 ± 3 248 ± 2 
HBL-100 5 8 ± 3 16 ± 6 1 ± 0.4 
  15 13 ± 4 27 ± 7 2 ± 0.5 
HS-576T 6 7 ± 2 15 ± 5 1 ± 0.2 
  17 8 ± 2 17 ± 5 1 ± 0.2 
MCF-7 7 185 ± 6 142 ± 4 12 ± 2 
  18 188 ± 7 145 ± 4 7 ± 2 
MDA-MB-231 1 16 ± 4 23  ± 5 2 ± 1 
  11 22 ± 4 25  ± 5 1 ± 0.5 
MDA-MB-435 2 16 ± 4 21 ± 5 0.1 ± 0.03 
  12 17 ± 4 22 ± 4 0.1  ± 0.2 
T47D 8 158 ±10 286 ± 1 131 ± 6 
  19 163 ± 10 279 ± 1 153 ± 7 
SKBR-3 9 14 ± 3 14 ± 3 268 ± 6 
  20 16 ± 3 14 ± 3 270 ± 1 
 
Tissue core ER  PR  HER2 
21 21 ± 3 51 ± 2 4 ± 1 
22 25 ± 2 74 ± 2 10 ± 1 
23 31 ± 2 30 ± 2 7 ± 1 
25 118 ± 3 59 ± 2 9 ± 1 
26 8 ± 1 140 ± 3  61 ± 3 
27 103 ± 4 7 ± 1 1 ± 0.3 
28 89 ± 2 47 ± 2 0.7 ± 0.1 
29 77 ± 5 86 ± 2 1 ± 0.3 
30 205 ± 4 10 ± 1 3 ± 0.5 
31 2 ± 0.2 211 ± 5 1 ± 0.2 
33 218 ± 11 5 ± 1 1 ± 0.4 
34 2 ± 0.4 20 ± 1 72 ± 5 
35 24 ± 2 4 ± 1 0.1 ±0.3 
36 14 ± 2 64 ± 2 90 ± 2 
37 103 ± 6 4 ± 1 2 ± 1 
38 61 ± 6 4 ± 0.4 40 ± 5 
39 32 ± 2 8 ± 1 39 ± 5 
41 4 ± 1 20 ± 1 22 ± 3 
42 8 ± 1 5 ± 1 1 ± 0.4 
43 87 ± 5 3 ± 1 0 ± 0 
44 63 ± 4 3 ± 1 27 ± 4 
45 5 ± 1 5 ± 1 15 ± 1 
 
aHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
bResults are an averaged HScore ± SD slides from twenty consecutive IHC slides stained by the SCH 
Laboratory.  
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Figure 14: Selected Tissue and Cell Core HScore QC Charts From the JGH CMLA HER2 
Controls. Fifty six consecutive controls were stained at JGH. The two cell line cores of low and 
high IHC-stain intensity (HScore = 0.3 ± 0.5 and 275 ± 19) were compared to the two tissue 
cores with the most similar IHC-stain intensity (HScore = 0.7 ± 1.1 and 194 ± 19).  Orange lines 
denote two SD from the mean HScore. Red lines denote three SD from the mean HScore. 
Values falling outside of 2 SD range indicate a need for recalibration of method and/or 
instrument. Values outside of 3 SD indicate the need for repeated testing because such results 
are unacceptable. A, the control containing sixteen breast tissue cores and two cell line cores 
(MDA-MB-231 and AU-565); B, comparison of low staining tissue and MDA-MB-231 cell line QC 
charts; C, comparison of high staining tissue and AU-565 cell line core QC Charts. 
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calibration materials. JGH control cell lines were not run in duplicate so no statistical 
comment on cell line homogeneity can be made. 
3.3.2 Functionality of cells and tissues as controls 
 
When used in QC control charts, HScores of both cell lines and tissue cores 
showed trending in staining performance. Samples out of ± 2 SD range could be 
observed using both control types. Cell line QC cores demonstrated biological 
homogeneity in IHC IA. Cell line QC charts had smaller SD and thus higher sensitivity in 
detecting true variation in calibration of the IHC system for ER and PR. IHC 
performance can be effectively monitored with a group of control cell lines with more 
than one staining intensity. 
3.3.3 Selection of FFPE cell line controls for EQA 
 
Cell lines AU-565 and HS-578T, AU-565 and MCF-7, and MCF-7 were identified as 
good midrange, positive controls for ER, PR and HER2, respectively. Cell lines MCF-7, 
T47D and AU-565 were selected as strongly positive controls for ER, PR and HER2, 
respectively. Cell line MDA-MB-231 is a low/ negative control for ER, PR and HER2. 
3.3.3.1 RT-qPCR of FFPE cell lines: ER, PR and HER2 gene expression 
 
A given set of FFPE cell lines blocks were analyzed by RT-qPCR and used to 
create a CLMA, which was stained for ER, PR and HER2 by five cIQc Program 
reference laboratories. Stained slides were visually assessed by cIQc Program 
assessors and by IA. RT-qPCR results for the nine cell lines were compared to IA 
HScore and pathologist assessment (Table 12). HScore levels of ER, PR and HER2 
correspond well with cIQc visual assessment and RT-qPCR values. The results add an 
additional level of confirmation to the IHC and IA-measured levels of ER, PR and HER2 
in the cell line samples. Results also indicate that the IHC-staining process, in itself, 
does not degrade ER, PR and HER2 in the nine FFPE cell lines prepared in this 
research. The use of the cell lines for daily positive controls as well as for EQA PT and 
evaluation of these markers is therefore possible, and can be performed by using IA. 
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Table 12: Comparison of IA HScorea, RT-qPCRb Transcriptional Expression 
Results and Expert Pathologist Scoring Resultsc for Individually Prepared Blocks 
of Nine FFPE Cell Linesd That Were IHC-Stained for ER, PR and HER2.  
 
 
 
 Average HScore  ± SD RT-qPCR transcription results Expert Assessment Scores 
Cell Line ER PR HER2 ER PR HER2 ER PR HER2 
AU-565 51 ± 24 49 ± 24 246 ± 36 0.1 <0.01 221.3 N N 3 
BT-474 69 ± 27 190 ± 28 248 ± 6 1.6 6.3 156.5 P P 3 
HBL-100 33 ± 27 26 ± 23 3 ± 3 <0.1 <0.1 2.8 N N 1 
HS-578T 45 ± 26 36 ± 23 1 ± 2 <0.1 <0.1 1.3 N N 0 
MCF-7 245 ± 22 168 ± 24 11 ± 9 8.9 0.5 2.6 P P 1 
MDA-MB-231 40 ± 23 34 ± 24 1 ± 1 <0.1 <0.01 1.9 N N 1 
MDA-MB-435 31 ± 16 33 ± 19 1 ± 1 0.8 0.4 0.1 N N 0 
SKBR3 37 ± 26 65 ± 60 260 ± 9 0.1 <0.1 156.5 N N 3 
T47D 188  ± 39 268 ± 6 72 ± 24 5.3 6.3 6.5 P P 2 
 
 
 
aHScores range from 0-300; HScore = (3*(3%+))+(2*(2%+))+(1*(1%+)). 
 
bRT-qPCR quantifies gene transcriptional expression from RNA extracted from the FFPE cell lines. 
Transcription levels are assumed to correlate with expression of ER, PR and HER2 within the samples. 
Sample results are expressed as ng protein equivalents, calculated by a relative quantification method 
that uses a calibrated external efficiency curve. The normalized gene copy numbers were adjusted using 
5 housekeeper genes. Duplicate sample results were averaged.  
 
cExpert assessment results are the average of EQA scoring results of slides analyzed by cIQc Program 
evaluating pathologists. Red cell line table squares are scored as positively stained (P), and white cell line 
squares are scored as negatively stained (N). For Her2, scores of 0 and 1 are negative and 2 and 3 are 
positive. 
 
dIA HScore Results are an average of analyzed IHC slides stained by five cIQc reference laboratories.  
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4. 0 DISCUSSION OF RESULTS 
4.1 IA in IHC 
4.1.1 Using IA in PT 
 
In this project, IA provided an accurate, reproducible measurement of IHC staining 
within and between EQA assessment runs. IA, when used in both in-laboratory daily 
quality control and in external, multiple-laboratory PT (EQA), produced satisfactory 
evaluative results. I conclude that IA can be used to monitor IHC results in PT.  
An important feature of IHC evaluation by IA is the removal of human imprecision in 
measuring IHC results as well as human bias. This project has demonstrated that IA 
measurement is an unbiased, reproducible/consistent tool for evaluating laboratory PT 
performance within and between different PT runs. This precise and reproducible 
measurement is an important improvement in both the performance evaluation of 
participating laboratories and the measurement of laboratory method calibration. This is 
particularly important for all Class II IHC tests for which evidence-based calibration is 
needed.  
Additionally, this study has also demonstrated the value of HScore and LSRSR for 
PT. HScore reflects an absolute amount of specific staining by IHC. Although the IHC 
system is not linear, it is considered to reflect the total amount of protein/epitope of 
interest. Despite this, an absolute HScore measurement has limited value in QA as 
there are no defined absolute reference measurements (gold standards) for any 
particular intensity of staining obtained for current samples used for PT. Also, there is 
no specific clinical use for absolute measurements, as there are none that define any 
disease or condition. The primary goal of PT is to compare calibration of the 
participating laboratories with reference laboratory results. Therefore, IA HScore data is 
more useful for assessing the calibration of the IHC procedure when converted into a 
LSRSR for PT evaluation, as a LSRSR reflects a measure of calibration relative to a 
reference laboratory 161. This is the first study to employ HScore for the calculation of 
the LSRSR, and to emphasize the value of a ratio and comparison to a designated 
reference value, rather than trying to assess HScore on its own. It is important to 
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emphasize that reference values will vary from one series of testing to another and 
there is no gold standard to provide an absolute HScore value that can be used for 
comparison between laboratories.  
4.1.2.1 Boxplots, histograms and Levey Jennings plots in PT 
 
EQA programs need a means for results/data presentation from their PT runs. This 
study has demonstrated how EQA programs can use histograms to show the relative 
performance of a laboratory to the total group of participating laboratories. This project 
also demonstrated the usefulness of IA-derived boxplots and histograms, including their 
being practical in presenting relative performance in IHC PT. Herein, for the first time, 
HScores and LSRSR values were used in the plotting results in Levey Jennings plots of 
both cell line and tissue reference cores with equal success. This study has 
demonstrated that graphical illustration of results achieved with low-, medium- and high-
expressing control cores is an excellent way of explaining EQA results to, and ensuring 
proper evaluation of, participating laboratories.  
4.1.2.2 Identification of informative cell lines and informative human tissue 
samples for monitoring of IHC calibration in PT 
 
This study evaluated which cell lines and tissue samples will be most informative for 
use in PT. To do this, I first had to determine which LSRSR ranges would be most 
informative to detect performance differences between participating laboratories. Initial 
IA analysis showed discriminatory LSRSR ranges for CLMA cores with HScore values 
in the range of 25 to 125. Subsequently, HScores of 50 to 150 were identified as 
practical and equally acceptable. Most importantly, both "very high" and "very low" 
staining cores were observed to have less discriminatory value. Therefore, samples with 
such HScores should not be selected for use in PT.  
This study also considered which tissue samples or cell line samples would perform 
best in detecting system variation for daily QC. It is not surprising that, similar to PT, the 
best positive controls samples to be used for QC are the same samples that are used 
for PT; samples that have discriminatory LSRSR ranges between 50 and 150 were the 
best. This was confirmed by the observation that the cell line controls for which the 
HER2 LSRSR was less diagnostic were the cell lines that had LSRSR values higher 
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than optimal (HScore >150). Therefore, I conclude that tissue or cell line samples 
selected for PT (EQA) and in-laboratory daily QC should have these diagnostically 
useful, intermediate HScore values whenever possible. I have also confirmed that when 
IA and LSRSR are employed, fewer PT samples are required than with expert 
assessment of PT results (which requires >30 samples) to yield that same information 
about laboratory performance in PT. This was only preliminary suggested in our 
previous study 161. Our current, and previous, studies indicate that LSRSR is an 
important EQA and QC tool. I, therefore, recommend the wide application of LSRSR in 
diagnostic IHC. 
4.1.2.2.1 IA as an evaluation tool in cIQc Run 13  
 
In Run 13 EQA, by using IA and LSRSR, I have identified more 
unacceptably/suboptimal results than with cIQc expert analysis (56%, 32% and 32% 
versus 34%, 25% and 5% for ER, PR and HER2, respectively). This initial work 
indicates that LSRSR appears to be a more sensitive discriminator by providing 
information about IHC protocol calibration, while the results of expert assessment 
provide different information (sensitivity, specificity, clinical validation). Both types of 
results are important for clinical IHC laboratories. Therefore, IA-derived LSRSR for both 
reference laboratories and participating laboratories in PT provides high-resolution 
evaluation of protocol calibration. IA is best employed in conjunction with biologically 
homogeneous cell line samples with informative HScores (ie., 50 – 150).  
A number of designated cIQc reference laboratories also had one or more LSRSR 
values that were outside of an acceptable LSRSR range. This means that there are 
reference laboratories that provide results with more variation than previously 
recognized. It also suggests that these reference laboratories may still require further 
optimization in their methodology to achieve better reproducibility of their results.  
Laboratories that participate in cIQc PT submit their protocols along with their 
stained slides. Since individual methods of the participating laboratories are available, 
consecutive PT followed by IA evaluations will facilitate improvement of the protocols 
and correlation of quality results with best methods, to further define best methods for 
IHC.  
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The cIQc Program uses a sufficient number of tissue samples (≥ 30) to enable the 
calculation of concordance, specificity, sensitivity, and κ to provide an assessment of 
participating laboratory performance characteristics. Due to the fact that the cIQc 
Program uses TMAs containing clinically representative human tissue samples, every 
PT run for ER, PR, and HER2 IHC is an external validation of the specific IHC protocols 
used in these tests. Despite this, the cIQc Program design and methods cannot be used 
to monitor specific IHC test calibration or to compare the calibration of the participating 
laboratories to the calibration of the reference laboratories. This is one of the most 
important roles of PT. 
cIQc expertly scored EQA runs require 30 or more cores for analysis, and require 
assessor time and travel. Otherwise, no calculations of concordance and inter-
laboratory reproducibility/variation are possible. This study showed, for the first time, 
that LSRSR is better than expert analysis for comparing IHC protocol calibration of 
participant laboratories to measurements obtained by the reference laboratory(-ies). 
This superiority is due to the reduced number of samples used and the fact that expert 
assessment is not required (reducing required time and travel costs). LSRSR reduces 
the number of samples required for PT while decreasing the turn-around time for issuing 
results of PT to participating laboratories.  
4.1.2.2.2 IA as a calibration tool in PT: Run 13 versus Special Run 
 
LSRSR in PT is best used as a calibration tool. This study has demonstrated that 
cell lines are more homogeneous in the expression of proteins than the human tissues 
currently used for either PT or QC. This is important if PT aims to monitor calibration of 
protocols. Human tissue samples are not very suitable for monitoring of IHC calibration 
because the differences detected between two or more tissue sections can be entirely 
due to biological tissue heterogeneity rather than protocol/system variation. Therefore, 
tissue samples are not particularly suitable as PT samples for monitoring of calibration.  
This study showed a significantly lower variation between different sections from 
blocks prepared from cell lines, in comparison to sections prepared from tissue blocks. 
IA, with consistent cell line controls, allows evaluation and monitoring of the IHC 
protocol calibration that is not possible with heterogeneous tissue controls. Importantly, 
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the high sensitivity of IA paired with LSRSRs enabled the detection of intervention in 
participating laboratories after they were informed that their results were suboptimal. In 
almost all laboratories that had such results, there was a shift in sensitivity and protocol 
calibration in the next round of testing, which was only detected by IA and LSRSR, but 
not with expert assessment. This study also demonstrated that the participating 
laboratories who received excellent results did not show any significant evidence of 
change in calibration. Therefore, I also conclude that an LSRSR derived via IA can be 
used to detect whether there was an attempt to improve protocols and test performance 
after a laboratory receives unacceptable results in PT.  Although statistically significant 
changes were not achieved for all three biomarkers, the ability to measure and 
demonstrate improvement and monitor protocol calibration of IHC is significant. This 
finely-tuned level of evaluation is simply not possible without the use of IA and LSRSRs. 
With successive cell line IHC PT runs, “optimal” HScore values and HScore ranges for 
each cell line will be better defined. This approach enables trend monitoring as well as 
correlation with protocol parameters to allow for the identification of suboptimal 
protocols and necessary method adjustment 20,161.  
Study results identified several laboratories with suboptimal PT performance, via 
stained cores with suboptimal LSRSRs that were not identified as suboptimal by cIQc 
expert assessment. The question is whether this level of increased sensitivity of PT is 
useful for participating laboratories, and ultimately, for patient care.  There is no intrinsic 
problem with increased sensitivity. The cut off levels for pass/fail could be changed or 
completely excluded from the reports, if necessary. It is advantageous for participating 
laboratories to have the opportunity to more precisely alter their protocol calibration 
towards an established gold standard. This gold standard is more informative and 
valuable than a simple pass/fail PT evaluation system. IA and LSRSR are superior to 
expert assessment because IA is objective and perfectly reproducible. There is also no 
cost for travel and accommodation of experts gathering for assessment from across 
Canada. This objectivity, reproducibility, and lower cost are all highly desirable in PT.   
The role of expert assessment still remains very important for the quality of EQA 
programs. Human tumor TMA samples should continue to be used to provide 
information about clinical IHC sensitivity, specificity, and κ with reference results. 
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Human tissue TMA results are better evaluated by expert assessment because IA 
cannot reliably differentiate tumors from benign tissues. Experts should be able to 
identify and interpret this intrinsic, biological heterogeneity. An expert pathologist's role 
is also to select superior reference samples and gold standards (or reference 
laboratories) for calculation of LSRSR.  
The level of calibration required for successful clinical practice could be identified 
through prospective studies that evaluated all of the samples from selected participating 
laboratories for a defined time period (e.g. 6 or 12 months), together with an appropriate 
reference laboratory. Only these semi-annual/annual audits would allow for final 
conclusions as to whether traditional expert assessment with human tissue TMAs or IA 
and LSRSR with cell line samples are more informative (or predictive of individual 
laboratory success with patient samples). It is generally understood that the PT and 
validation requirements traditionally applied in liquid-based assays (such as those 
frequently used in clinical chemistry laboratories) are not applicable for the evaluation of 
cell-based assays like IHC and flow cytometry with currently used methods. However, 
IA and LSRSR introduce a new methodology and a radical modification of current 
methods. I contend that using IA and LSRSR can move IHC towards the same QA 
standards as those used in liquid-based assays.  
4.1.3 Use of IA in QC: HScore and QC charts in daily control evaluation 
 
This project is the first demonstration of functional QC chart plotting of tissue and 
cell line IHC IA HScore data for in-laboratory/daily QA. Cell line-based IHC controls 
were more diagnostically useful, due to their superior functionality over tissue controls 
for ER and PR IHC. QA was optimal when QC charts were paired with biologically 
homogeneous, reproducible cell line control samples.  
4.1.3.1 IA and IHC QA with current tissue controls 
 
This study showed that current tissue-based positive IHC controls, when evaluated 
by IA and LSRSR, can also be used for creating QC charts. However, this study also 
quantifiably demonstrated the biological tissue heterogeneity of these controls. This 
heterogeneity is a potential source of variation that interferes with the primary purpose 
of controls. Controls need to be stable and consistently produce the same result. Both 
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tumor and benign human tissue show unacceptable variation in expression of an 
epitope/protein of interest. Although this variation is difficult to measure, document and 
follow with visual inspection, IA is excellent for this purpose. IA is sufficiently sensitive 
and reproducible, and is suitable for monitoring daily-run on-slide IHC controls for 
tissues.  
The present study showed that, although tissue is biologically heterogeneous, this 
heterogeneity could be minimized by using larger tissue samples. Based on the results, 
the use of larger tissue samples is recommended, irrespective of the method for 
detection of results (visual inspection by microscope or IA). This is an effective 
approach in decreasing overall tissue heterogeneity.  
This study also investigated different currently used tissues for their performance in 
daily QC. IHC-stain variation in control tissues from one day to another was examined 
using IA HScore. While it seems logical to use breast tumor tissue as a breast marker 
IHC control, this may not always be possible or practical due to variable tissue quality 
and availability. Examination of current control tissues from a number of hospitals did 
not conclusively determine a superior IHC control tissue for ER, PR and HER2. Breast 
tissue, endometrial tissue and a combination of endometrium and breast tissue all 
performed adequately. As discussed above, the size of the control was more important 
than tissue type as a parameter of sample quality. A group of the same tissue type with 
a range of known stain intensities is recommended by current national IHC guidelines 
43,53. 
This study also demonstrated that cell lines do not show biological heterogeneity for 
measured analytes from one level to another in a paraffin block.  For this reason, cell 
lines are superior to human tissues as control samples. This has been concluded from 
the Final CLMA experiments where slides containing both FFPE tissue and cell line 
controls were stained in a single reference laboratory with previously demonstrated, 
optimal IHC PT performance. These successive runs showed that even in runs in which 
cell lines showed no variation from day to day, tissues occasionally showed 
unacceptable measurement. This tissue sample measurement variation may be falsely 
interpreted as system variation. This false suggestion of variation is unacceptable in a 
control sample. Therefore, these results suggest that cell line controls are a superior 
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alternative to human tissue controls. Cell line-based calibration models were confirmed 
as applicable daily positive controls for Class II IHC tests that could be monitored by IA 
with Levey Jennings QC charts. 
4.1.3.2 FFPE QC standards 
 
CAP, cIQc and NordiQC recommend that IHC laboratories run and monitor daily 
IHC controls, where percent positive tumor cells and stain intensity are recorded. 
Samples with various levels of expression of epitope of interest are recommended, 
while the use of a single sample with high expression of epitope of interest is 
discouraged, since it may be misleading 33,53,108. Samples with very high expression 
levels do not provide any information about the level of system calibration 20,33,43.  
It has been shown in many PT runs that a poorly performing laboratory is not 
able to identify their own poor performance most of the time because of the use of 
inappropriate controls in their daily QC 177.  Unfortunately, standardization of controls for 
clinical IHC has not been achieved yet and appropriate reference materials are still 
undefined. RT-qPCR results for the ER, PR and HER2 mRNA in the cell lines used in 
this study confirmed that IA appropriately measures IHC-stained levels of ER, PR and 
HER2 in the CLMA blocks, and that cell line manipulation and processing into paraffin 
blocks and subsequent manipulation by HIER does not significantly alter true biological 
levels of ER, PR and HER2 in FFPE tissue samples. This confirmation is important for 
CLMAs to be accepted as usable for IHC QA and PT in the future.   
4.2 Characteristics of Cell Line Samples for ER, PR and HER2 IHC Controls 
 
Study results suggest that by using IA, LSRSR, and selected cell lines as reference 
materials, standardization of IHC control samples can be done. The cell lines used need 
to have an HScore between 50 and 150 and need to be run as duplicate samples. Each 
paraffin block containing the cell line samples needs to be tested by a reference 
laboratory to produce reference results for each paraffin block. An increase in the 
density of cells in the cell pellets of the FFPE blocks to 4 X 107 cells in 300 µL is also 
desirable (i.e., compared to 2.0 X 107 cells in 300 µL as used in this thesis research). 
This higher cell density was suggested by expert cIQc pathologists as more desirable 
for use in IHC evaluation (personal communication, Blake Gilks and Emina Torlakovic). 
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While small variations in FFPE cell lines have been observed from batch to batch, 
these batch variations are not relevant when each set of results is correlated/calibrated 
using samples from within the same batch. In addition, each batch of cell lines will 
produce a large number of paraffin blocks with similar IHC IA results. This means that 
only a small number of different cell line batches are required to provide controls for a 
large amount of daily laboratory testing. It is entirely possible to produce a sufficient 
number of paraffin blocks for an end user for an entire year, from one cell line batch. For 
example, if a laboratory runs approximately 300 IHC tests for each of ER, PR, and 
HER2 per year, only two paraffin blocks would be required as controls for each test 
type.  
I have identified useful reference/control cell lines for ER, PR and HER2 IHC. These 
cell lines are listed in Section 3.3 and Section 3.3.3. Previous studies looking at ER, PR 
and HER2180 selected MCF-7, T47D and BT-474 as strongly staining cell lines for ER, 
PR and HER2, respectively. My results also observed this strong staining for these 
same cells. Dako currently uses MDA-MB-231 as a negative (Her2 score, 0) cell line 
and SK-BR3 as a strongly positive (Her2 score, 3+) cell line as a part of their HER2 IHC 
HerceptestTM 129. My study results are in agreement with this research. However, I have 
also identified a number of intermediately staining breast cancer cell lines, which were 
shown to provide better resolution and allow more precise monitoring during IHC 
calibration. In addition, since both AU-565 and SKBR-3 cells similarly express HER2, 
only one of them needs to be used for making control samples. Also, both cell lines are 
difficult to culture, but the AU-565 cell line is faster growing and more robust, making it 
my recommended choice. Also, HBL-100 is a normal breast cell line181 and was not 
selected as one of the recommended cell line control for any of the breast markers in 
this study. For this reason, HBL-100 cells also could be excluded to reduce labor and 
costs. From the cell lines tested, a CLMA control for ER, PR and HER2 IHC containing 
the cell lines AU-565, BT-474, HS-578T, MCF-7, MDA-MB-231, MDA-MB-435 and 
T47D is best.  
4.2.1 Other considerations 
 
IA is a very sensitive system. It has been previously demonstrated that the 
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thickness of a slide section must be carefully controlled because it can affect IHC-stain 
intensity. Thicker sections of FFPE cell lines have shown increased IHC staining 182. For 
this reason, I recommend that the CLMA control slides used for calibration and QA be 
sectioned consistently, in the laboratories they are used in, to reduce this error. This is 
particularly important for the consistent IA evaluation used for PT, so that true variation 
in method or instrument performance can be measured.  
The applications of this study are limited to FFPE samples and are restricted, at the 
moment, to ER, PR and HER2 IHC-stained human tissue. Study ideology can be 
applied on a larger scale to address other epitopes and proteins of interest if other cell 
lines are prepared in this manner and stained with other appropriate IHC methods and 
antibodies. QC charts could be used as suggested in clinical QC, either with large tissue 
controls or, ideally, with cell line controls in the optimal manner described. Further 
LSRSR analysis of future EQA runs will yield more data regarding the expanded 
applications of the results of this study. It is important to remember that the currently 
used clinical IHC methods and antibodies used in these methods are not fully 
standardized. As such, the limitations of the study are also related to the current quality 
of methodology used for IHC staining. As IHC improves, the results of this study will 
have wider applications.  
4.3 Issues still remaining with IA  
 
Since the start of this project, the practice of digital pathology has expanded to 
enhance training in, and the application of, digital pathology. Although this study shows 
that IA can be used for both PT and QC, a few remaining issues with IA need to be 
addressed. 
IA cannot yet reliably identify tumor tissues or damaged samples. Although this is 
not relevant to cell line samples, it is entirely relevant for currently used human tissue 
controls. Pathologists use IHC to observe ER, PR, or HER2 protein expression in 
individual tumor cells and their subcellular location in positive cells. Expert assessment 
of human tumor samples prepared as TMAs for PT will exclude results from benign 
breast tissue. IA is unable to perform at that level in PT. Efforts to modify IA to reliably 
separate tumor and normal tissue were unsuccessful. Consequently, if IA is to be used 
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in PT with human tissue samples, the selection of samples for IA analysis must be done 
manually, prior to analysis. This is very labor intensive and is not possible to do, as it 
would make PT prohibitively expensive. I have partly addressed this problem by 
evaluating the effects the size of tested samples on detected error and true differences 
in protocol variation. IA scanning of human tissue samples was more consistent for 
larger samples. Smaller samples increased the error related to biological variations 
within the tissue (normal versus tumor). Smaller samples also increased the difference 
in measurement between different slide sections cut from the same paraffin block. 
Using cell lines instead of tissue as controls solved these two IA problems. 
Although IA is reproducible and objective, section folding irrespective of source (cell 
lines or human tissue samples), will produce erroneous results. Therefore, any unusual 
IA LSRSR results must be examined as to their cause. I recommend post-scanning 
evaluation, because visual scoring of IHC samples is time consuming and it is 
impractical to screen every core on every slide prior to IA. This applies to both control 
samples in daily QC and samples used for PT.  In this project, any unusual LSRSR 
results were easily clarified and corrected using post-scanning analysis. Currently, 40 
tissue cores are used in PT for ER, PR and HER2 IHC, which could be replaced by a 
minimum of 3 cell line samples in the future. This would greatly simplify this post-
scanning visual inspection for core folding because of the much shorter time needed.   
4.3.1 Advances in IA and improvements in diagnostic IHC  
 
The use of IA and digital microscopy in IHC will increase as the technology 
becomes more widely available and the cost of it decreases. However, until IHC 
methodology is standardized, it may be impractical to define and apply IA in a strictly 
quantitative manner. One of the most important messages of this work is that 
standardization of the overall, clinically applied, IHC is not possible without 
standardization of both the control samples used for both daily QC (with patient 
samples) and the samples used for PT (to compare each testing center with other 
testing centers and reference values). IA can help these developments.  
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4.4 Qualitative and Quantitative IHC: Are we there yet?  
 
All IHC is currently qualitative, irrespective of how the results of IHC are used. 
Basically, the results are designated as positive or negative. There is a traditional, non-
scientific cut off point of 10% cells with staining, used as a cut off point for interpreting 
IHC results as “positive”. This is considered “qualitative IHC” and is used by 
pathologists for the interpretation of most Class I IHC tests that are employed to 
determine cell differentiation. For example, if the tumor is “positive” for cytokeratin, this 
favors the diagnosis of carcinoma versus the diagnosis of lymphoma. Most quantitative 
IHC is reduced, in clinical practice, to semi-quantitative scoring systems. The most 
frequent one is 0 to 3+. No cut off points are precisely defined and this system is not 
considered to be highly reproducible. Most recently, higher precision was recommended 
for Class II IHC tests with great consequence for patient treatment. In particular, 
ASCO/CAP guidelines for ER and PR IHC testing recommend a cut off at 1% weakly 
positive cells as a “positive result”, declaring a patient eligible for hormonal therapy. The 
same recommendations ask for the use of HScore, or a similar scoring system, in which 
both intensity of staining and the percentage of positive cells is reported 43,45. Additional 
methods have been developed for HER2 scoring since the start of this project 183.  
One would assume that appropriate control systems (adequate for detecting errors 
at clinically significant cut off points) are available for daily QC of IHC testing. This is not 
the case. The recommended controls are generally a combination of tumor and benign 
tissues with no defined levels of expression. There is a discrepancy between the 
recommendation for precise evaluation of patient results and the lack of standardization 
of controls for QC. For these reasons, EQA programs that provide PT (like the cIQc 
Program) are seeking for answers to this problem.  
This project has provided evidence of how to make better control samples together 
with recommendations for IA of the results. This will be very helpful, if applied in clinical 
practice. Also, my recommended evaluation with LSRSR enables the use of relatively 
inexpensive cell lines. The absolute levels of measured epitope in these useful cell lines 
is not relevant, as long as they are in the high resolution (intermediate) HScore range 
and a “gold standard” reference result for the each particular batch of cell lines is 
available. This applicable “gold standard” may be dictated by a provincial health 
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authority (for example, provincial reference laboratory results or national reference 
laboratory results) and was not a subject of this study.  
4.5 Future prospects for IA, LSRSR and cell lines  
 
The cIQc Program is eager to use CLMAs (as defined in this work) and LSRSR in 
their future ER, PR and HER2 IHC EQA evaluations, as well as other Class II PT. The 
cIQc Program has the facilities and expertise to culture large batches of cells for the 
preparation of FFPE cell line controls and provide “gold standard” results for these 
cultured cell lines. It is vital to have a single, consistent source of cell line control 
materials for clinical laboratory use. Although it is entirely acceptable for any center to 
develop these controls, many laboratories do not have the time, skills or funding 
required to reproducibly create FFPE CLMA controls or determine “gold standard” 
results for them. Both of these parameters are important and necessary, for reasons 
previously discussed. If a single provider of controls for PT and QC could be 
established, Canada would be the first country in the world to have standardized control 
samples for clinical/diagnostic IHC.  
Optimally, CLMAs, IA, and the calculation of LSRSR would be combined as follows 
in daily QC for any laboratory that performs clinical IHC testing. A CLMA or cell line 
mixture control paraffin block (prepared commercially or by a designated center of 
excellence) would have the first cut slide stained by the designated reference laboratory 
and method. The remaining block would provide about 200 sections/control samples to 
be used in the diagnostic IHC laboratory for daily QC. The calculated LSRSR would be 
recorded on the Levey Jennings plots for each IHC test. This is very similar to currently 
run control samples in clinical chemistry laboratories. This approach enables proper 
calibration with a reference laboratory, as well as the daily monitoring of performance 
trends within a given diagnostic laboratory.  The so-called "Westgard rules" 113 for 
monitoring controls could be evaluated in further studies for their applicability to this 
system. 
A mixture of cells prepared as a cell block could also be considered for control 
sample preparation, which would obviate the need for creating a composite cell line 
microarray. A future study could be to create and evaluate a FFPE cell pellet control 
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containing a mixture of two cell lines. The preparation of this carefully quantified 50:50 
mixture would require precise culturing of pre-selected cell lines by an experienced 
technologist. A scoring method for percentage of total cells staining positive denoting 
"successful" staining would need to be defined for scoring by IA or visual assessment. A 
negatively-staining, negative control cell line would be paired with an intermediately-
staining, discriminatory cell line, with an optimal combination selected for each IHC 
epitope of interest. A strongly positive cell line control would not be necessary, because 
I have shown that such cell lines are not discriminatory for IHC calibration or evaluation. 
Drawing from my study results, I suggest the following combinations. The MDA-MB-231 
cell line would function as a negative control for all three breast markers. Based on 
expert visual assessment in this project, I suggest the discriminatory cell line HS-578T 
or AU-565 for ER and PR, and cell line T47D for HER2, respectively. For IA assessment 
I recommend BT-474, MDA-MB-435 and MCF-7 for ER, PR and HER2 respectively, 
based on their HScore values in this project. For initial evaluation, paraffin blocks 
containing these mixtures could have cores added from individual FFPE cell lines 
(and/or known validated tissues) so that a comparison with current controls could be 
made. These controls could be evaluated as part of a cIQc breast cancer marker EQA 
run, to determine whether these mixtures would accomplish, essentially, the same PT 
control function as a CLMA, with reduced costs and preparation time.  
I also envision a partnership with national and international IHC suppliers. 
Companies like Dako and Roche may be interested in selling these standardized 
controls on their own, or as a part of an entire IHC quality package, where 
instrumentation, reagents, controls and evaluation methods could be combined to 
optimize the entire procedure (in a manner similar to other clinical diagnostic tests). The 
optimized cell line samples, used as proposed here, would much cheaper than currently 
available cell line controls 129. The price would be lower because this proposed system 
does not require an extremely precise monitoring of the absolute levels of the analyte of 
interest. The analyte only needs to be expressed in the cell lines in the approximate 
HScore linear range, which is wide (50 – 150). The innovative use of LSRSR is the key 
to this approach, because it is not critically important that clinical laboratories know what 
the absolute IHC levels are - merely how their results compare to designated “gold 
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standard” (thus making LSRSR very important). Additionally, this innovative use of IA 
enables the daily monitoring of controls on Levey Jennings plots, which is critical for 
detecting unacceptable system variation and errors. This is the first suggestion that PT 
(an important component for laboratory accreditation) can be standardized with QC 
charts. Connecting daily QC and clinical IHC performance to EQA evaluation makes this 
prospective method very clinically relevant.  
4.6 Study Conclusions  
 
1. IA can be used in diagnostic IHC PT, for EQA, to rank individual laboratory 
performance (in comparison to reference laboratory performance), using HScore and 
LSRSR. This method is more sensitive and more cost-efficient than currently used 
expert assessment methods.  
 
2. A small number of cell line-based calibration samples are applicable in IHC PT and 
can be used in place of current TMA models, as they provide the same or more 
information than currently used TMA models for the calibration of IHC protocols. 
However, they cannot replace TMA samples for IHC validation. A combined cell line-
based and human TMA sample-based methodology is recommended for use by EQA 
programs in order to provide both monitoring of calibration and a validation of IHC 
protocols.  
 
3. Cell line-based calibration models are applicable as daily positive controls for Class II 
IHC tests. This type of controls can be evaluated by IA and monitored by using LSRSR 
and Levey Jennings-QC charts. IA QC charts allow precise observation trending in IHC 
performance, particularly when paired with cell line control samples.  
 
Using IA with LSRSR to evaluate cell line controls is critical in the optimization and 
calibration of IHC methodology. Other cell lines can be evaluated as possible controls 
for other these and other Class II biomarkers. Through the diligent work of the cIQc, 
NordiQC and CAP Programs, IA has the potential to improve breast cancer diagnosis 
and treatment in Canada and around the globe. 
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6.0 APPENDICES 
 
6.1 Appendix A: List of chemicals and reagents used. 
 
Ammonium hydroxide   Fisher Scientific, Ottawa, ON   
   
Antibody dilution buffer   Dako, Goldstrup, Denmark 
 
AU-565 cell lines    Dr. Deborah Anderson Laboratory 
 
Autostainer IHC buffer, 10X   Dako 
 
BT-474 cell lines    Dr. Erique Lukong Laboratory 
 
Copper sulphate, heptahydrate  Fisher Scientific 
 
Delimiting pen (hydrophobic  Dako 
marker for autostainer) 
 
DMEM cell culture medium   ATTC, Manassas, VA 
(Dulbecco/Vogt Modified Eagle's  
Minimal essential medium) 
 
Dimethyl sulfoxide (DMSO),  Sigma Chemical Co., St. Louis, MO 
 
Ethylenediamintetraacetic acid  EMD Millipore, Billerica, MA 
(EDTA) 
 
Envision Plus IHC stain kit for   Dako 
mouse IgG   
 
Envision Plus IHC kit for rabbit IgG Dako 
  
Estrogen receptor antibody,   Thermo Scientific, Waltham, MA   
rabbit monoclonal anti-human 
(clone SP1)    
 
Fetal bovine serum (FBS), cell  Gibco, Burlington, ON 
culture grade, sterile 
 
Ethanol     Fisher Scientific  
 
Formalin, 10% Buffered   Royal University Hospital  
      (Surgipath Medical Ind., Richmond, IL) 
 
HBL-100 cell line    Dr. Svein Carlsen Laboratory 
  118 
 
Hematoxyllin 1     Richard Allen Scientific,     
      Kalamazoo, MI 
 
HemosIL Thrombin Time kit  Beckman Coulter, Mississauga, ON 
 
HS-578T cell line    Dr. John Decoteau Laboratory 
 
Human epidermal growth factor   Thermo Scientific 
receptor 2, rabbit monoclonal      
antibody (Clone SP3)          
 
HUMULIN®R, biosynthetic human Eli Lilly's and Co., Toronto, ON 
insulin, 100 U/mL           
 
Human plasma, AB–    Royal University Hospital,  
      Saskatoon, SK 
 
Isopropanol     Fisher Scientific 
 
αMEM cell culture medium   Gibco  
 
nitrogen, liquid    Praxair, Saskatoon, SK 
 
Paraplast paraffin     Surgipath Medical Ind.,     
      Richmond, IL 
 
Isopropanol     Fisher Scientific 
 
McCoy’s 5A cell culture medium  ATTC  
 
MCF-7 cell line    Dr. Svein Carlsen Laboratory 
 
MDA-MB-231 cell line   Dr. John Decoteau Laboratory 
 
MDA-MB-435 cell line   Dr. John Decoteau Laboratory 
 
Penicillin/Streptomycin, 100X, sterile Gibco 
 
Permount mounting media   Fisher Scientific 
 
pH calibration buffers (4, 7 and 10) Fisher Scientific 
 
Progesterone receptor antibody,   Novocastra, (Leica GmbH) Concord, ON 
mouse monoclonal anti-human    
(Clone 16)    
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Qiagen DNA clean-up kit*   Qiagen, Valencia, CA 
 
Qiagen Total RNA extraction kit*  Qiagen 
 
Roche MasterMix*    Roche Diagnostics, Indianapolis, IN 
 
RPMI 1640 cell culture medium, 1X Gibco  
(Roswell Park Memorial Institute cell  
culture medium, 1640 variation) 
 
RPMI 1640 cell culture medium, 1X Gibco 
high glucose with 4-(2-hydroxyethyl) 
-1-piperazineethanesulfonic acid  
(HEPES) (Roswell Park Memorial  
Institute cell culture medium, 1640  
variation) 
  
SKBR-3 cell line    Dr. Deborah Anderson Laboratory 
 
Sodium bicarbonate, 100mM, sterile  Gibco 
  
Sodium pyruvate, 100 mM, sterile  Gibco 
 
Superscript III, reverse transcriptase* Invitrogen, Grand Island, NY 
      
T47D cell line    Dr. John Decoteau Laboratory 
 
Tween 20     Dako 
 
0.4% Trypan blue, sterile    Gibco 
 
0.05% Trypsin/EDTA with phenol red  Gibco 
 
Xylene, histology grade     Fisher Scientific 
 
 
 
* Used by the Bernard Laboratory for RT-qPCR Analysis 
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6.2 Appendix B: List of solutions and media used. 
 
Bluing solution hematoxyllin enhancing solution: 0.5 mL ammonium hydroxide in 
200 mL dH20. Make fresh daily. 
 
Cell Culture media formulations for individual cell lines: Table B1 (below) contains 
specific media preparations for each cell line. All media contain 100 U/mL penicillin and 
100 µg/mL streptomycin. 
 
Copper sulphate DAB enhancing solution: 2% (w/v) copper (II) sulphate in dH20 
 
Dako Envision Plus IHC Kit (mouse IgG kit) contains prediluted peroxidase block 
solution, prediluted HRP conjugated secondary anti-mouse antibody and DAB 
chromagen solution(1 drop DAB, 1 mL DAB buffer).  
 
Dako Envision Plus IHC Kit (Rabbit IgG kit): contains prediluted peroxidase block 
solution, prediluted HRP conjugated secondary anti-rabbit antibody and DAB 
chromagen solution(1 drop DAB, 1 mL DAB buffer).  
 
D-PBS (calcium and magnesium free): 4.0 g NaCl, 0.1 g KCl, 0.87 g Na2HPO4, 
dibasic, 0.1 g KH2PO47H20, monobasic dissolved in 450 mL rdH20 water. pH solution 
to 7.4 (if needed), bring to 500 mL and autoclave. 
 
D-PBS with 2 mM EDTA: D-PBS with 0.2922 g EDTA added prior to autoclaving  
 
10 mM EDTA stock solution: 2.9224 g EDTA in 1 L dH20. 
 
1 mM EDTA, pH 9.0 HIER buffer: Dilute 50 mL 10 mM EDTA solution with 400 mL 
dH20. pH solution to 9.0 with 1 mM NaOH and bring to 500 mL with dH20. 
 
70% Ethanol: 700 mL 100% ethanol and 300 mL dH20 
 
95% Ethanol: 950 mL 100% ethanol and 50 mL dH20 
 
HemosIL Thrombin Time kit: Mix 2 mL kit buffer concentrate with 4 mL sterile distilled 
water. Use 6 mL buffer to reconstitute 1 vial of dried thrombin. Incubate 30 min. Mix 
equal amounts thrombin solution with human AB plasma to create a clot. 
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Table B1: Media and Growth Conditions for CLMA Cell Lines 
 
Cell Line Growth Media  Passage 
AU-565 RPMI 1640
1 high glucose with HEPES2 + 
10% FBS3 1:3 at <50% confluency 
BT-474 DMEM4  + 10% FBS 1:3 at 70% confluency 
HBL-100 RPMI 1640  + 20% FBS 1:4-1:6 at 95% confluency 
HS-578T RPMI 1640  + 10% FBS + 0.2 U/mL Humulin®R5 1:4-1:6 at 95% confluency 
MDA-MB-231 RPMI 1640  + 10% FBS 1:6 at 95% confluency 
MDA-MB-435 RPMI 1640  + 10% FBS 1:6 at 95% confluency 
 
MCF-7 
 
αMEM6  + 10% FBS + 1mM sodium 
pyruvate +0.01mg/L Humulin®R + 1.5 
g/L sodium bicarbonate. 
1:4 – 1:6 at <70% confluency 
SKBR-3 McCoy’s 5A7 + 10% FBS  1:3 at <50% confluency 
T47D   RPMI 1640*  + 10% FBS 1:4-1:6 at 95% confluency 
 
All media contain 100 U/mL penicillin and 100 µg/mL streptomycin.  
1RPMI 1640, Roswell Park Memorial Institute cell culture medium, 1640 variation 
2HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
3FBS, fetal bovine serum 
4DMEM, Dulbecco/Vogt Modified Eagle's Minimal essential cell culture medium 
5Humulin®R, Biosynthetic human insulin  
6αMEM – α-Modified Minimum Essential Medium Eagle cell culture medium 
7McCoy’s 5A, McCoy’s 5A cell culture medium 
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6.3 Appendix C. List of instruments and relevant materials used. 
 
Autostain Plus IHC Autostainer  Dako, Goldstrup, Denmark 
System 
 
Autostainer reagent vials, 15 mL  Dako 
 
Biosafety Cabinet    Nuare Laboratory Equipment,    
      Plymouth, MN 
 
Cell culture flasks (T25, T75)    BD Falcon, Mississauga, ON 
 
Centrifuge, benchtop   VWR Canlab, Mississauga, ON 
 
Centrifuge tubes, 15mL and 50 mL,  BD Falcon 
capped, sterile 
 
CO2 humidified growth incubator   VWR Canlab 
 
Coverslips     VWR Canlab 
 
Cryopreservation chamber   Invitrogen, Burlington, ON  
(Isopropanol)   
 
Cryovials     VWR Canlab 
 
Cytospin 4      Shandon Inc., PA, USA 
 
EZ-Slides     EMD Millipore, Billerica, MA 
 
Filter funnels for cytospin   Biomedical Polymers Inc., Gardner, MA 
 
Forceps     VWR Canlab 
 
Haemocytometer     Hausser Scientific, Horsham, PA 
 
Histological grade, tissue paper  Surgipath Medical Ind., Richmond, IL 
 
Histology embedding cassettes  Surgipath Medical Ind. 
 
Microarrayer, Beecher MTA-1  Beecher Instruments, Sun     
      Prairie, WI 
 
Microscope, reverse field      Nikon, Mississauga, ON 
 
Microscope, regular    Nikon 
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Microscope slides, positively charged  VWR Canlab 
 
Micropipettors    Eppendorf, Mississauga, ON 
 
Microtome, Leica RM2235 -   Leica GmbH, Concord, ON 
  
Microwave, 1100 watt    Panasonic, Mississauga, ON 
 
Oven, incubating    VWR Canlab 
 
Petri plates, plastic, sterile   VWR Canlab 
 
Pipette tips, sterile, filtered   Diamed Lab Supplies Inc., Mississauga, ON 
 
PipetteAid     Drummond Scientific Co., Broomall, PA 
 
Pipettes, 5 mL, 10 mL& 25 mL,   Fisher Scientific, Ottawa, ON 
plastic, wrapped, sterile 
 
Pipettes, glass    Fisher Scientific 
 
Razor blades     VWR Canlab 
 
RT-PCR Thermocycler,    Roche Diagnostics, Indianapolis, IN 
Lightcycler480 RT-PCR*     
 
Sample collection containers,  Fisher Scientific 
125 mL, plastic, sterile 
 
Scanscope CS IA System    Aperio, Vista, CA 
 
Tissue Embedding Console, Sakura  Saksura Finitech, Alphen aan den   
      Rijn, The Netherlands  
 
Tissue Tek TEC 5      Andwin Scientific, Schaumburg, IL 
 
TissueTek II slide trays    Andwin Scientific 
 
TissueTek II histology staining rack Andwin Scientific 
  
Tubes, 0.5 mL     Diamed Lab Supplies Inc.  
 
Waterbath     Fisher Scientific 
 
 
* Used by the Bernard Laboratory for RT-qPCR Analysis 
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6.4 Appendix D: List of software used for analysis 
 
IA Nuclear algorithm#   Aperio, Vista, CA 
(as modified by cIQc) 
 
IA Membrane algorithm#   Aperio 
 
Imagescope (Version 10)   Aperio  
 
Microsoft Office (2007 & 2011)  Microsoft, Redmond, WA 
 
Photoshop CS    Adobe, San Jose, CA 
 
Profiler™ PCR Array Data    Qiagen (formerly SABiosciences) 
Analysis Software*    Valencia, CA 
 
Spectrum (version 11)   Aperio 
 
SPSS (Version 19)    IBM, Armonk, NY 
 
TMALab Version 10)   Aperio 
 
 
 
#Algorithm detailed settings are listed in Supplemental Table 1. 
*Used by the Bernard Laboratory for RT-qPCR Analysis 
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6.5 Supplemental Table 1: IA Algorithms. A, Nuclear Algorithm Settings for scoring 
ER and PR staining. B, Membranous Algorithm settings for scoring HER2 staining. Any 
changes from Aperio standard algorithms are marked with bold italics. 
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6.6 Supplemental Table 2: cIQc Run 13 Assessment results  
 
cIQc 
Laboratory 
ER IHC concordance 
with cIQc reference ER κ
a PR IHC concordance  with cIQc reference PR κ
a PR IHC concordance with cIQc reference HER2 κ
a 
101 35/37 (95%) 0.88 30/33 (91%) 0.82 33/36 (92%) 0.82 
102 44/45 (98%) 0.95 44/45 (98%) 0.96 37/41 (90%) 0.81 
103 41/43 (95%) 0.89 39/44 (89%) 0.78     
105 41/42 (98%) 0.95 38/41 (93%) 0.85 38/40 (95%) 0.9 
106 47/47 (100%) 1 42/43 (98%) 0.95 36/39 (92%) 0.84 
107 44/45 (98%) 0.95 40/46 (87%) 0.74 38/39 (97%) 0.95 
108 38/40 (95%) 0.88 39/40 (98%) 0.95 38/38 (100%) 1 
109 35/38 (92%) 0.81 36/38 (95%) 0.89 37/37 (100%) 1 
110         32/38 (84%) 0.69 
111 42/47 (89%) 0.74 43/45 (96%) 0.91 40/42 (95%) 0.9 
112 30/32 (94%) 0.87 40/43 (93%) 0.86 40/40 (100%) 1 
113 40/46 (87%) 0.67 38/39 (97%) 0.95 40/41 (98%) 0.95 
114 41/42 (98%) 0.94 45/46 (98%) 0.96 42/42 (100%) 1 
115 41/43 (95%) 0.89 39/42 (93%) 0.86 32/33 (97%) 0.94 
116 33/40 (83%) 0.54 38/39 (97%) 0.95     
117 36/38 (95%) 0.86 40/40 (100%) 1 20/21 (95%) 0.9 
118 37/41 (90%) 0.78 39/43 (91%) 0.82 35/37 (95%) 0.89 
120 36/38 (95%) 0.87 28/28 (100%) 1 37/38 (97%) 0.94 
122 30/43 (70%) 0.42 39/42 (93%) 0.86     
123 38/42 (90%) 0.79 32/39 (82%) 0.64     
124 35/41 (85%) 0.69 29/37 (78%) 0.58 42/43 (98%) 0.95 
125 40/43 (93%) 0.84 38/43 (88%) 0.77     
126 24/29 (83%) 0.58 26/29 (90%) 0.79 28/28 (100%) 1 
127 24/26 (92%) 0.82 23/24 (96%) 0.91 31/31 (100%) 1 
128 28/29 (97%) 0.92 33/34 (97%) 0.94     
129 32/35 (91%) 0.82 30/34 (88%) 0.77 33/34 (97%) 0.94 
132 24/27 (89%) 0.78 28/30 (93%) 0.87     
133 31/34 (91%) 0.81 35/36 (97%) 0.94 35/35 (100%) 1 
134 21/35 (60%) 0.14 19/37 (51%) 0.03 35/37 (95%) 0.89 
135 40/43 (93%) 0.85 41/42 (98%) 0.95 38/41 (93%) 0.85 
138 33/36 (92%) 0.82 34/39 (87%) 0.75     
139 36/38 (95%) 0.88 34/35 (97%) 0.94 25/25 (100%) 1 
140 32/35 (91%) 0.82 35/36 (97%) 0.94 37/39 (95%) 0.89 
141 38/43 (88%) 0.74 40/44 (91%) 0.81     
143 39/41 (95%) 0.89 32/35 (91%) 0.83     
144 41/44 (93%) 0.85         
145 36/41 (88%) 0.72 38/40 (95%) 0.9 40/40 (100%) 1 
146 35/37 (95%) 0.89 35/36 (97%) 0.94     
147 42/48 (88%) 0.73 35/37 (95%) 0.89 29/36 (81%) 0.62 
148 43/44 (98%) 0.95         
149 22/24 (92%) 0.83 41/45 (91%) 0.82 40/43 (93%) 0.86 
150 41/44 (93%) 0.84 37/38 (97%) 0.95 34/34 (100%) 1 
151 30/39 (77%) 0.47 31/43 (72%) 0.45 36/40 (90%) 0.79 
153 28/33 (85%) 0.68 38/42 (90%) 0.81 37/39 (95%) 0.89 
154 33/36 (92%) 0.82 35/36 (97%) 0.94     
155 34/37 (92%) 0.82 32/33 (97%) 0.94 32/33 (97%) 0.94 
156 33/35 (94%) 0.88 34/36 (94%) 0.89 36/37 (97%) 0.94 
157 40/40 (100%) 1 37/42 (88%) 0.76 35/36 (97%) 0.94 
158 39/41 (95%) 0.89 41/42 (98%) 0.95 38/40 (95%) 0.9 
159 33/35 (94%) 0.88 37/39 (95%) 0.9     
160 34/35 (97%) 0.94 32/35 (91%) 0.83 31/32 (97%) 0.93 
161 25/27 (93%) 0.83 26/27 (96%) 0.92 28/28 (100%) 1 
164 27/32 (84%) 0.66 30/30 (100%) 1 31/31 (100%) 1 
167 19/21 (90%) 0.8 24/28 (86%) 0.72 24/24 (100%) 1 
168 21/23 (91%) 0.81 21/22 (95%) 0.9     
170 35/38 (92%) 0.81 25/27 (93%) 0.85 33/34 (97%) 0.94 
172 23/31 (74%) 0.42 28/30 (93%) 0.86     
173 26/30 (87%) 0.71 30/34 (88%) 0.76     
174 29/32 (91%) 0.81 28/32 (88%) 0.75     
175 30/32 (94%) 0.87 30/32 (94%) 0.88 27/28 (96%) 0.92 
177 25/27 (93%) 0.83 25/30 (83%) 0.67     
178 30/34 (88%) 0.75 27/34 (79%) 0.6     
% Acceptable 66% 69% 75% 73% 95% 93% 
  
aCohen's κ calculated between laboratory IHC results and cIQc IHC assessed staining results 
 
